var title_f15_31_15856="Late acromegalic arthropathy";
var content_f15_31_15856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late acromegalic arthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain film of the hands shows the changes in late acromegalic arthropathy. The abnormalities include tufting of the terminal phalanges, widening of the joint spaces of the metacarpophalangeal joints, and degenerative changes, seen particularly in the thumb and first carpometacarpal joints and in the proximal interphalangeal joint of the right little finger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Verna Wright, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15856=[""].join("\n");
var outline_f15_31_15856=null;
var title_f15_31_15857="Pelvic congestion syndrome";
var content_f15_31_15857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ovarian venogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 478px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left ovarian venogram on a 44-year-old woman with chronic pelvic congestion syndrome. There is filling of both markedly dilated ovarian veins (arrows) via venous reflux and interconnecting uterine venous plexus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15857=[""].join("\n");
var outline_f15_31_15857=null;
var title_f15_31_15858="Carbohydrate content medications";
var content_f15_31_15858=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74620&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carbohydrate content of selected pediatric medications for oral administration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strength, flavor, US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Carbohydrate grams*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Analgesics and antipyretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen elixir",
"       </td>",
"       <td>",
"        160 mg per 5 mL, Tylenol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Acetaminophen liquid suspension",
"       </td>",
"       <td>",
"        160 mg per 5 mL, cherry, Tylenol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 mg per 5 mL, grape, Tylenol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        4.8 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen tablet chewable",
"       </td>",
"       <td>",
"        80 mg per tablet, fruit flavor, Tylenol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.25 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acetaminophen with codeine elixir",
"       </td>",
"       <td>",
"        120 mg acetaminophen and 12 mg codeine per 5 mL, fruit punch, Capital",
"        <sup>",
"         &reg;",
"        </sup>",
"        and codeine",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ibuprofen suspension",
"       </td>",
"       <td>",
"        100 mg per 5 mL; berry, bubble gum, grape; Motrin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 mg per 5 mL, tropical punch, Motrin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ibuprofen tablet chewable",
"       </td>",
"       <td>",
"        50 mg per tablet, orange, Motrin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.3 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 mg per tablet, orange, Motrin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.6 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Anti-asthmatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Montelukast tablet chewable",
"       </td>",
"       <td>",
"        4 or 5 mg per tablet, cherry, Singulair",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.2 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Montelukast granules",
"       </td>",
"       <td>",
"        4 mg per packet, Singulair",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 per packet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Anticonvulsants (also see benzodiazepines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbamazepine suspension",
"       </td>",
"       <td>",
"        100 mg per 5 mL, citrus-vanilla, Tegretol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.7 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbamazepine tablet chewable",
"       </td>",
"       <td>",
"        100 mg per tablet, Tegretol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.3 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ethosuximide syrup",
"       </td>",
"       <td>",
"        250 mg per 5 mL, raspberry, Zarontin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Felbamate solution",
"       </td>",
"       <td>",
"        600 mg per 5 mL, Felbatol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Lamotrigene orally disintegrating tablet",
"       </td>",
"       <td>",
"        25 or 50 mg per tablet, cherry, Lamictal",
"        <sup>",
"         &reg;",
"        </sup>",
"        ODT&trade;",
"       </td>",
"       <td>",
"        0.1 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100 mg per tablet, cherry, Lamictal",
"        <sup>",
"         &reg;",
"        </sup>",
"        ODT&trade;",
"       </td>",
"       <td>",
"        0.3 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 mg per tablet, cherry, Lamictal",
"        <sup>",
"         &reg;",
"        </sup>",
"        ODT&trade;",
"       </td>",
"       <td>",
"        0.6 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamotrigene chewable dispersible tablet",
"       </td>",
"       <td>",
"        2, 5, 25 mg per tablet, black currant, Lamictal",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levetiracetam solution",
"       </td>",
"       <td>",
"        100 mg per mL, grape, Keppra",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxcarbazepine suspension",
"       </td>",
"       <td>",
"        300 mg per 5 mL, Trileptal",
"        <sup>",
"         &reg;",
"        </sup>",
"        (contains ethanol)",
"       </td>",
"       <td>",
"        7.75 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenytoin tablet chewable",
"       </td>",
"       <td>",
"        50 mg per tab, Dilantin Infatab",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phenytoin suspension",
"       </td>",
"       <td>",
"        125 mg per 5 mL, orange-vanilla, Dilantin-125",
"        <sup>",
"         &reg;",
"        </sup>",
"        (ethanol 0.6 percent)",
"       </td>",
"       <td>",
"        1.4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valproate (divalproex) capsule sprinkle",
"       </td>",
"       <td>",
"        125 mg per capsule, Depakote",
"        <sup>",
"         &reg;",
"        </sup>",
"        Sprinkle",
"       </td>",
"       <td>",
"        0.05 per capsule",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valproate (valproic acid) syrup",
"       </td>",
"       <td>",
"        250 mg per 5 mL, Depakene",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        4.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vigabatrin suspension packet",
"       </td>",
"       <td>",
"        500 mg per packet, Sabril",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cetirizine syrup",
"       </td>",
"       <td>",
"        5 mg per 5 mL, grape, Zyrtec",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cetirizine tablet chewable",
"       </td>",
"       <td>",
"        10 mg per tab, grape Zyrtec",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desloratadine orally disintegrating tablet",
"       </td>",
"       <td>",
"        5 mg per tab, tutti-fruti, Clarinex RediTab&reg;",
"       </td>",
"       <td>",
"        0.2 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dimenhydrinate tablet chewable",
"       </td>",
"       <td>",
"        50 mg per tab, orange, Dramamine",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenhydramine liquid",
"       </td>",
"       <td>",
"        12.5 mg per 5 mL, cherry, Benadryl",
"        <sup>",
"         &reg;",
"        </sup>",
"        children's allergy",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphenhydramine liquid",
"       </td>",
"       <td>",
"        12.5 mg per 5 mL, bubble gum, Benadryl",
"        <sup>",
"         &reg;",
"        </sup>",
"        children's dye free allergy",
"       </td>",
"       <td>",
"        1.3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fexofenadine syrup",
"       </td>",
"       <td>",
"        30 mg per 5 mL, berry, Allegra",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fexofenadine orally disintegrating tablet",
"       </td>",
"       <td>",
"        30 mg per tab, orange cream, Allegra",
"        <sup>",
"         &reg;",
"        </sup>",
"        Children's Allergy",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxyzine suspension",
"       </td>",
"       <td>",
"        25 mg per 5 mL, Vistaril",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxyzine syrup",
"       </td>",
"       <td>",
"        10 mg per 5 mL, Atarax",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loratadine orally disintegrating tablet",
"       </td>",
"       <td>",
"        10 mg per tab, citrus or bubble gum, Alavert",
"        <sup>",
"         &reg;",
"        </sup>",
"        Children's Allergy",
"       </td>",
"       <td>",
"        0.2 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Amoxicillin suspension",
"       </td>",
"       <td>",
"        50, 125, 200, 250 or 400 mg per 5 mL, Amoxil",
"        <sup>",
"         &reg;",
"        </sup>",
"        (Dava generic: bubble gum; Sandoz or Teva: berry)",
"       </td>",
"       <td>",
"        1.6 to 1.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        125 or 250 per 5 mL, Trimox",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Amoxicillin tablet chewable",
"       </td>",
"       <td>",
"        125 mg per tab, berry, Amoxil",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        250 per tab, berry, Amoxil",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.3 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Amoxicillin and clavulanate suspension",
"       </td>",
"       <td>",
"        200, 400 or 600 mg per 5 mL, orange or strawberry, Augmentin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;0.1 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        125 or 250 mg per 5 mL, banana or orange, Augmentin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Amoxicillin and clavulanate tablet chewable",
"       </td>",
"       <td>",
"        125 or 200 mg per tab, cherry banana, Augmentin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1 to 0.2 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        250 or 400 mg per tab, cherry banana, Augmentin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.4 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Omnipen",
"        <sup>",
"         &reg;",
"        </sup>",
"        (Dava generic: bubble gum)",
"       </td>",
"       <td>",
"        4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin suspension",
"       </td>",
"       <td>",
"        100 mg per 5 mL, cherry-vanilla-banana, Zithromax",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefaclor suspension",
"       </td>",
"       <td>",
"        125, 187, 250 or 375 mg per 5 mL, Ceclor",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.6 to 3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefadroxil suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Duricef",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefdinir suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Omnicef",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.8 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefixime suspension",
"       </td>",
"       <td>",
"        100 mg per 5 mL, Suprax",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.7 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefpodoxime suspension",
"       </td>",
"       <td>",
"        50 or 100 mg per 5 mL, Vantin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefprozil suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Cefzil",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefuroxime axetil suspension",
"       </td>",
"       <td>",
"        125 mg per 5 mL, Ceftin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephalexin suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Keflex",
"        <sup>",
"         &reg;",
"        </sup>",
"        (Teva generic: berry)",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciprofloxacin suspension",
"       </td>",
"       <td>",
"        250 or 500 per 5 mL, strawberry, Cipro",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clarithromycin suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Biaxin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.3 to 3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clindamycin solution",
"       </td>",
"       <td>",
"        75 mg per 5 mL, cherry, Cleocin Pediatric",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin suspension",
"       </td>",
"       <td>",
"        200 or 400 mg per 5 mL, Eryped",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin estolate suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL, Ilosone",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Erythromycin ethylsuccinate suspension",
"       </td>",
"       <td>",
"        200 or 400 mg per 5 mL, E.E.S.",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.5 g per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 mg per 5 mL granules, E.E.S.",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin tablet chewable",
"       </td>",
"       <td>",
"        200 mg, EryPed",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.4 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythromycin and sulfisoxazole suspension",
"       </td>",
"       <td>",
"        200 or 600 mg per 5 mL, cherry berry, E.S.P.",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Fluconazole suspension",
"       </td>",
"       <td>",
"        50 or 200 mg per 5 mL, Teva or Greenstone generic",
"       </td>",
"       <td>",
"        2.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 or 200 mg per 5 mL, orange, Diflucan",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        14 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loracarbef suspension",
"       </td>",
"       <td>",
"        100 or 200 mg per 5 mL, Lorabid",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3 to 3.2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nystatin suspension",
"       </td>",
"       <td>",
"        500,000 units per 5 mL",
"       </td>",
"       <td>",
"        3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL",
"       </td>",
"       <td>",
"        2.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin V potassium suspension",
"       </td>",
"       <td>",
"        125 or 250 mg per 5 mL",
"       </td>",
"       <td>",
"        2.5 to 3.3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim and sulfamethoxazole suspension",
"       </td>",
"       <td>",
"        40 mg trimethoprim and 200 mg sulfamethoxazole per 5 mL, grape, Septra",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zidovudine syrup",
"       </td>",
"       <td>",
"        50 mg per 5 mL, strawberry, Retrovir",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Benzodiazepines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alprazolam solution",
"       </td>",
"       <td>",
"        1 mg per mL, Alprazolam Intensol&trade;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam solution",
"       </td>",
"       <td>",
"        1 mg per mL",
"       </td>",
"       <td>",
"        0.2 per ONE mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diazepam solution concentrate",
"       </td>",
"       <td>",
"        5 mg per mL, Diazepam Intensol&trade; (ethanol 19 percent)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lorazepam solution",
"       </td>",
"       <td>",
"        2 mg per mL, Lorazepam Intensol&trade;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Gastrointestinals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium carbonate antacid suspension",
"       </td>",
"       <td>",
"        400 mg per 5 mL, Mylanta",
"        <sup>",
"         &reg;",
"        </sup>",
"        Children's suspension",
"       </td>",
"       <td>",
"        1.75 g per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cimetidine solution",
"       </td>",
"       <td>",
"        300 mg per 5 mL, Tagamet",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2.8 g per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Docusate sodium syrup",
"       </td>",
"       <td>",
"        20 mg per 5 mL",
"       </td>",
"       <td>",
"        1.4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esomeprazole packet",
"       </td>",
"       <td>",
"        20 or 40 mg per packet, Nexium",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3 per packet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Famotidine suspension",
"       </td>",
"       <td>",
"        40 mg per 5 mL, Pepcid",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Lansoprazole orally disintegrating tablet",
"       </td>",
"       <td>",
"        15 mg, Prevacid",
"        <sup>",
"         &reg;",
"        </sup>",
"        SoluTab&trade;",
"       </td>",
"       <td>",
"        0.17 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30 mg, Prevacid",
"        <sup>",
"         &reg;",
"        </sup>",
"        SoluTab&trade;",
"       </td>",
"       <td>",
"        0.34 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loperamide",
"       </td>",
"       <td>",
"        1 mg per 5 mL, Imodium",
"        <sup>",
"         &reg;",
"        </sup>",
"        A-D",
"       </td>",
"       <td>",
"        4.1 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium hydroxide",
"       </td>",
"       <td>",
"        400 mg per 5 mL, mint, Milk of Magnesia",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magaldrate simethicone suspension",
"       </td>",
"       <td>",
"        5 mL, Riopan",
"        <sup>",
"         &reg;",
"        </sup>",
"        plus",
"       </td>",
"       <td>",
"        0.4 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Magnesium hydroxide, aluminum hydroxide, simethicone",
"       </td>",
"       <td>",
"        5 mL regular or double strength, Mylanta",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.7 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metoclopramide syrup",
"       </td>",
"       <td>",
"        5 mg per 5 mL, Reglan",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.75 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polyethylene glycol 3350",
"       </td>",
"       <td>",
"        17 gram per packet, Miralax",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ranitidine syrup",
"       </td>",
"       <td>",
"        75 mg per 5 mL, Zantac",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ranitidine granules",
"       </td>",
"       <td>",
"        150 mg per packet, Zantac Efferdose",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Saccharomyces boulardii packet",
"       </td>",
"       <td>",
"        250 mg per packet, Florastor",
"        <sup>",
"         &reg;",
"        </sup>",
"        kids",
"       </td>",
"       <td>",
"        0.5 per packet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Senna syrup",
"       </td>",
"       <td>",
"        5 mL, Senokot",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Simethicone",
"       </td>",
"       <td>",
"        40 mg per 0.6 mL, Mylicon",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;0.1 per 0.6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone elixir",
"       </td>",
"       <td>",
"        0.5 mg per 5 mL, raspberry, Baycadron&trade; (ethanol 5.1 percent)",
"       </td>",
"       <td>",
"        1.7 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexamethasone solution concentrate",
"       </td>",
"       <td>",
"        1 mg per mL; Dexamethasone Intensol&trade; (ethanol 30 percent)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisolone solution concentrate",
"       </td>",
"       <td>",
"        15 mg per 5 mL, Orapred",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.9 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisolone syrup concentrate",
"       </td>",
"       <td>",
"        15 per 5 mL, Prelone",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        3.6 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisolone solution",
"       </td>",
"       <td>",
"        5 mg per 5 mL, Pediapred",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisolone syrup",
"       </td>",
"       <td>",
"        5 mg per 5 mL, Prelone",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        2 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone solution",
"       </td>",
"       <td>",
"        5 mg per 5 mL",
"       </td>",
"       <td>",
"        1.8 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone solution concentrate",
"       </td>",
"       <td>",
"        5 mg per mL, Prednisone Intensol&trade;",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Vitamin and mineral supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium carbonate suspension",
"       </td>",
"       <td>",
"        1250 mg per 5 mL",
"       </td>",
"       <td>",
"        1.5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ferrous sulfate drops",
"       </td>",
"       <td>",
"        75 mg per 1 mL, Fer-In-Sol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.6 per ONE mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ferrous sulfate syrup",
"       </td>",
"       <td>",
"        90 mg per 5 mL, Fer-In-Sol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        6.3 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, vitamins A, D, E, C, folic acid chewable tablet",
"       </td>",
"       <td>",
"        12 mg iron per tab, Vi-Daylin",
"        <sup>",
"         &reg;",
"        </sup>",
"        chewable with iron",
"       </td>",
"       <td>",
"        0.4 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, vitamins A, D, E, C drops",
"       </td>",
"       <td>",
"        20 mg iron per mL, Vi-Daylin",
"        <sup>",
"         &reg;",
"        </sup>",
"        + Iron drops",
"       </td>",
"       <td>",
"        0.75 per ONE mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, vitamins, A, D, E, C liquid",
"       </td>",
"       <td>",
"        10 mg iron per 5 mL, Vi-Daylin",
"        <sup>",
"         &reg;",
"        </sup>",
"        liquid with iron",
"       </td>",
"       <td>",
"        5 per 5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron, vitamins B, D drops",
"       </td>",
"       <td>",
"        10 mg iron per mL, Poly-Vi-Sol",
"        <sup>",
"         &reg;",
"        </sup>",
"        with iron",
"       </td>",
"       <td>",
"        0.9 per ONE mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple vitamin and mineral supplement liquid",
"       </td>",
"       <td>",
"        15 mL, Centrum",
"        <sup>",
"         &reg;",
"        </sup>",
"        Advanced Formula Liquid",
"       </td>",
"       <td>",
"        6.25 per 15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Multiple vitamin and mineral supplement tablet chewable",
"       </td>",
"       <td>",
"        One tab, Bugs Bunny, Centrum",
"        <sup>",
"         &reg;",
"        </sup>",
"        Kids Rugrats&trade;, Flintstones",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        &lt;0.7 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugar-free types",
"       </td>",
"       <td>",
"        &lt;0.4 per tab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D drops",
"       </td>",
"       <td>",
"        8000 units per mL, Drisdol",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin E drops",
"       </td>",
"       <td>",
"        15 units per 0.3 mL, Aquasol E",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        0.1 per 0.3 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Approximate maximum grams of total carbohydrate, including sugars, per usual dose unit.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15858=[""].join("\n");
var outline_f15_31_15858=null;
var title_f15_31_15859="Amniocentesis PI";
var content_f15_31_15859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amniocentesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 496px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During amniocentesis the doctor uses a needle to remove a small sample of the fluid that surrounds the fetus. This fluid is called \"amniotic fluid.\" As part of the procedure, the doctor uses an ultrasound machine to get a picture of the uterus and other organs. The picture shows up on a screen and helps the doctor decide where to place the needle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15859=[""].join("\n");
var outline_f15_31_15859=null;
var title_f15_31_15860="Polymyxin B: Patient drug information";
var content_f15_31_15860=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Polymyxin B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     see \"Polymyxin B: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25012?source=see_link\">",
"     see \"Polymyxin B: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug has not been fully studied in pregnant women. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shot: May cause kidney function to get worse and cause trouble breathing, and it may change your sense of balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to polymyxin B or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the bladder as a wash sometimes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11886 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-86B232FEE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15860=[""].join("\n");
var outline_f15_31_15860=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016088\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016090\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016089\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016094\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016095\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016097\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016092\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016093\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016098\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016099\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=related_link\">",
"      Polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25012?source=related_link\">",
"      Polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15861="Initial treatment of HIV";
var content_f15_31_15861=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Initial treatment of HIV (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/31/15861/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15861/contributors\" id=\"au136\">",
"       John G Bartlett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/31/15861/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15861/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/31/15861/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15861/contributors\" id=\"de8449\">",
"       Allyson Bloom, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/31/15861?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIV TREATMENT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Being diagnosed with HIV can be an overwhelming experience, filled with worry about the future, concern for loved ones, and fears of dying. However, current treatment regimens have significantly improved the possibility of living with HIV. In fact, living with HIV is similar to living with other chronic diseases, such as diabetes or high blood pressure; when HIV is closely monitored and treated, it may be possible to control the disease for a lifetime.",
"    </p>",
"    <p>",
"     This article discusses treatment options for HIV, including general information about when to start treatment and issues to consider when starting treatment. A discussion of treatments to prevent opportunistic infections is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=see_link\">",
"      \"Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHO TREATS HIV?",
"     </span>",
"    </p>",
"    <p>",
"     Anyone who is diagnosed with HIV is best managed by a doctor who specializes in the care of people with HIV or AIDS. Physicians in your area usually know the best local doctors who are experts in HIV care.",
"    </p>",
"    <p>",
"     If you are newly diagnosed with acute HIV infection, consider enrolling in a clinical trial. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of currently used treatments. Clinical trials are conducted all over the world. Ask for more information about clinical trials from a healthcare provider, or read about current trials at",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHEN TO START HIV TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The time to start antiretroviral treatment (ART) for HIV depends upon several factors, including your T cell count, age, underlying medical conditions, history of an AIDS-defining illness, and your willingness to commit to lifelong treatment. Each of these factors is discussed in detail below. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"      \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      T cell count",
"     </span>",
"     &nbsp;&mdash;&nbsp;T helper cells, also known as CD4 cells, are white blood cells that help to organize the immune system. A low T cell count indicates that your immune system is not healthy and that there is a significant risk of developing an opportunistic infection. An opportunistic infection is one that is uncommon in people with a healthy immune system but that can develop as the immune system fails.",
"    </p>",
"    <p>",
"     A person with HIV gradually develops lower T cell counts over time as the immune system weakens. The lower the T cell count, the higher the risk of developing opportunistic infections, particularly in patients with T cell counts &lt;200",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </p>",
"    <p>",
"     Over the last several years, guidelines have continued to change regarding the optimal time to start HIV therapy. Several years ago, treatment was recommended only in patients who had fewer than 350 T",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"     Subsequently, the T cell threshold was increased to 500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"     Expert groups now recommend starting all patients with HIV on treatment regardless of T cell count.",
"    </p>",
"    <p>",
"     There are two main reasons why treatment is now recommended at higher T cell counts:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       ART may also reduce the risk of non-AIDS-related complications, such as cancer, premature heart disease, cognitive function and premature aging. There is now some evidence that early treatment may slow or prevent these complications.",
"      </li>",
"      <li>",
"       Current HIV medications are less toxic than earlier HIV medications, and the combination regimens are easier to take",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Benefits of ART",
"     </span>",
"     &nbsp;&mdash;&nbsp;The urgency to start treatment is based to a large extent on the T cell count. The lower the T cell count, the more urgent it is to start treatment. The normal T cell count is 500 to 1400",
"     <span class=\"nowrap\">",
"      cells/mL.",
"     </span>",
"     When it is below 200, the risk of serious infectious disease complications increases, and this risk increases the more the T cell count drops. There is a definite benefit to starting treatment when the T cell count is 200 to 500",
"     <span class=\"nowrap\">",
"      cells/mL",
"     </span>",
"     and now indirect evidence of benefit when it is over 500.",
"    </p>",
"    <p>",
"     Treatment of HIV also prevents transmission of HIV. Therefore, successful treatment nearly eliminates the risk of transmission to an unborn child in pregnancy or sexual transmission to an uninfected partner (see below). &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Risks of ART",
"     </span>",
"     &nbsp;&mdash;&nbsp;The potential risks of ART include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Once started, HIV treatment is usually lifelong. You must take your medicines regularly. Taking a \"break\" from treatment can significantly increase your risk of developing drug resistance or opportunistic infections. Be sure to tell your doctor or nurse if you need to stop because of an illness, surgery, or loss of insurance. Be certain to refill your medications on time.",
"      </li>",
"      <li>",
"       The medicines used for HIV all have possible side effects that you need to be aware of, since a few are serious and require discontinuation of the drug. Most side effects can be managed by changing the regimen.",
"      </li>",
"      <li>",
"       The medicines for HIV are expensive but are usually paid for by insurance or government programs. Your provider or a social worker will know the rules on this.",
"      </li>",
"      <li>",
"       The various HIV regimens differ greatly in terms of \"pill burden\" (total",
"       <span class=\"nowrap\">",
"        pills/day),",
"       </span>",
"       pill size, food requirements, and side effects. Some HIV medications cannot be taken with other pills due to drug interactions. Your provider will be able to review these issues, often with the help of a pill chart. (See",
"       <a class=\"local\" href=\"#H12\">",
"        'Patient preference'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The decision to start ART means that you are ready to commit to a lifetime of taking medications on a daily basis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies have shown untreated HIV-infected patients over the age of 50 develop AIDS faster and do not survive as long after being infected with HIV compared with younger people. As a result, people who are HIV-positive and older than 50 years are often advised to start ART, regardless of their T cell count. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=see_link\">",
"      \"HIV and the older patient\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If you and your doctor or nurse decide to wait to start ART, be sure you are followed closely and get laboratory testing (every three to six months) to monitor for new AIDS-related illnesses (eg, thrush, weight loss) or rapid decline in your T cell count, which would indicate the need to start treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;ART is recommended to all HIV-positive women who are pregnant, regardless of their T cell count. The reason for this recommendation is that taking ART can significantly decrease the risk that you will transmit HIV to your infant during pregnancy or birth.",
"    </p>",
"    <p>",
"     Detailed information about pregnancy and HIV treatment is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"      \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Sexually active individuals",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are HIV-positive and sexually active with a partner(s) who is HIV-negative might want to start ART to decrease the risk of transmitting their infection, regardless of their T cell count. The probability of transmitting the infection depends on the amount of virus in the blood. With \"no detectable virus,\" the risk is small, but not zero. Safe sex (using condoms every time) also significantly reduces the risk of transmitting HIV.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Underlying medical conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;HIV treatment is often recommended for people with certain underlying medical conditions, regardless of their T cell count. This includes the following conditions:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       HIV-associated nephropathy (kidney disease caused by HIV)",
"      </li>",
"      <li>",
"       HIV-associated changes in brain functioning",
"      </li>",
"      <li>",
"       Hepatitis B or hepatitis C",
"      </li>",
"      <li>",
"       Cardiovascular disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      AIDS-defining illnesses",
"     </span>",
"     &nbsp;&mdash;&nbsp;AIDS-defining illnesses are diseases or conditions that are uncommon in people with a healthy immune system, but can develop in people with a severely weakened immune system (as a result of AIDS).",
"    </p>",
"    <p>",
"     Antiretroviral treatment is strongly recommended for anyone who has a current or past history of one or more of these illnesses, regardless of his or her T cell count.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Patient preference",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risks and benefits of starting antiretroviral treatment are largely dependent on the T cell count.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The chances of becoming ill or dying from an HIV-related condition are small when your T cell count is greater than 500",
"       <span class=\"nowrap\">",
"        cells/microL.",
"       </span>",
"       Thus, the benefit of antiretroviral treatment to prevent these complications due to poor immune function is likely to be small. However, treatment may decrease the risk of other complications, such as premature heart disease or brain dysfunction, which may be related to uncontrolled HIV virus in the body. Once ART is started, you will take it for your lifetime. Stopping treatment has no clear benefit, and some people will develop an increased viral load",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       decreased T cell count when off ART.",
"      </li>",
"      <li>",
"       The long-term effects of ART are still unknown, especially with the newer medications.",
"      </li>",
"      <li>",
"       Taking HIV drugs inconsistently (eg, not on time every day) can sometimes lead to drug resistance, which may eventually limit the number of drugs that work to keep your disease controlled. The likelihood of drug resistance depends upon which medicines you take and how many days or weeks of pills you miss.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For these reasons, the decision to start antiretroviral treatment when your T cell count is greater than 500",
"     <span class=\"nowrap\">",
"      cells/microL",
"     </span>",
"     depends upon your age, underlying medical conditions, and your preferences. An experienced HIV healthcare provider can help you to make this decision.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      PREPARING FOR HIV TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Before starting treatment, you will have blood tests and a complete physical examination. These tests can help to determine whether you have any underlying HIV-related infections or other illnesses. In addition, testing is recommended to determine whether your virus is resistant to any HIV medications and to ensure that the most effective anti-HIV treatments are used.",
"    </p>",
"    <p>",
"     There is no one medication regimen that is \"best\" for all patients. The following factors are important to consider:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       How many pills will I need, and how many times per day will I take a dose? Pills that contain a combination of two or three drugs are now available and can reduce the number of pills you need to take per day. Most initial treatment regimens require one to four pills per day.",
"      </li>",
"      <li>",
"       Do I need to take the medicine at a certain time or",
"       <span class=\"nowrap\">",
"        with/without",
"       </span>",
"       food? It can be difficult for some people to take their medicines on time, depending upon work, school, or family obligations. Having to take the medicine on an empty stomach or with food can make it even more difficult to take the medicine correctly. However, many of the medicines used for HIV have no special food requirements.",
"      </li>",
"      <li>",
"       Are the medicines covered by insurance or government programs? If yes, is the co-pay affordable? If no, are there alternatives that are covered? Given that the medications will be needed indefinitely, it is important to be sure they are affordable.",
"      </li>",
"      <li>",
"       What are the possible short-term and long-term side effects of the medicines? It is important to be aware of the potential side effects of your HIV medicines. Your doctor or nurse should describe the most common side effects.",
"      </li>",
"      <li>",
"       Are there any potential drug interactions with my current medicines? HIV medicines can interact with other medications, which can cause the medication to be less effective or require a change in dose. For example, some HIV medications interfere with methadone; a higher dose of methadone may be needed to avoid symptoms of methadone withdrawal.",
"      </li>",
"      <li>",
"       Will this medicine affect my other illnesses (eg, hepatitis, diabetes, heart disease)? A minority of patients taking HIV medicines will develop drug-related liver inflammation. This risk is increased in patients with underlying chronic viral hepatitis. People who have hepatitis and require anti-HIV medicines should be aware of potential medicine-related side effects, including nausea, vomiting, right upper abdominal pain, fatigue, loss of appetite, and yellowed skin or whites of the eyes. Report these problems to your doctor or nurse immediately.",
"      </li>",
"      <li>",
"       How long will I need to take the medicine? Once you start HIV medicines, you will probably need to take them for the rest of your life. In clinical trials that allowed people to stop their HIV medicines temporarily, there was no clear benefit, and some people developed an increased viral load",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       decreased T cell count.",
"      </li>",
"      <li>",
"       If you are female, are you considering becoming pregnant in the future? One medicine, efavirenz, is not recommended during pregnancy due to the risks to the developing baby in the first trimester. A discussion of HIV and pregnancy is available separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"        \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      HOW DO HIV MEDICATIONS WORK?",
"     </span>",
"    </p>",
"    <p>",
"     Human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. Retroviruses contain several targets that are disrupted by medicines that treat HIV.",
"    </p>",
"    <p>",
"     Medicines used to treat HIV are called antiretroviral drugs. These are usually given as a combination of three drugs, known as highly active antiretroviral treatment (ART). There are several classes of antiretroviral medicines:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Non-nucleoside reverse transcriptase inhibitors (NNRTIs)",
"      </li>",
"      <li>",
"       Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)",
"      </li>",
"      <li>",
"       Protease inhibitors (PIs)",
"      </li>",
"      <li>",
"       Fusion inhibitors (not usually included in initial treatment)",
"      </li>",
"      <li>",
"       Integrase strand transfer inhibitors (INSTIs)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The decision about which medications to use will depend on many issues, such as whether or not you have any drug resistance to any HIV medications.",
"    </p>",
"    <p>",
"     Detailed information about the side effects and best ways to take these medicines is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"      \"Patient information: Tips for taking HIV medications (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Goals of therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following are goals of antiretroviral treatment for HIV:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Suppress the HIV virus to prevent it from multiplying. The goal is to have no detectable virus in the blood for as long as possible. At this level, the virus is essentially \"shut down.\"",
"      </li>",
"      <li>",
"       Improve quality of life",
"      </li>",
"      <li>",
"       Preserve future treatment options, meaning that there will be drugs available if you develop toxicity or resistance to some drugs",
"      </li>",
"      <li>",
"       Restore immune function (as indicated by T cell count) (see",
"       <a class=\"local\" href=\"#H4\">",
"        'T cell count'",
"       </a>",
"       above). The goal is to see the T cell count increase by 100 to 200",
"       <span class=\"nowrap\">",
"        cells/microL",
"       </span>",
"       during the first few years of treatment and then remain high.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      ART regimens",
"     </span>",
"     &nbsp;&mdash;&nbsp;ART regimens are commonly referred to as having a base and a backbone. As an example:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The base is either a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor, or an integrase inhibitor. A small dose of ritonavir is often given to \"boost\" the base PI.",
"      </li>",
"      <li>",
"       The backbone typically consists of two NRTIs",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Each medicine has specific dosing instructions, side effects, and interactions with other prescription, nonprescription, and herbal medications. This section provides specific information about each medicine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Non-nucleoside reverse transcriptase inhibitors (NNRTIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;NNRTIs inhibit the action of an enzyme, reverse transcriptase, which prevents or limits HIV from copying itself. Specific information about NNRTIs is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef74973 \" href=\"UTD.htm?32/60/33739\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Protease inhibitors (PIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Proteases are enzymes that HIV requires to copy itself. Thus, protease inhibitors can prevent or limit the virus's ability to copy itself. When proteases are blocked, HIV makes copies of itself that cannot infect new cells. This can reduce the amount of virus in the blood and increase the number of T cells. Specific information about protease inhibitors is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef68715 \" href=\"UTD.htm?5/17/5405\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;NRTIs are incorporated into the DNA of HIV, which helps to prevent the virus from copying itself. Pills that contain a combination of NRTIs are often recommended to reduce the number of pills you must take. Specific information about NRTIs is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef76285 \" href=\"UTD.htm?11/5/11357\">",
"      table 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A blood test is recommended before starting one of the NRTIs, abacavir, to determine whether you are at risk for developing a serious allergic reaction.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Integrase inhibitors (INSTIs)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Integrase is an enzyme that HIV requires to make copies of itself. Raltegravir (MK-0518) is the first drug available in this class and is effective in patients who are starting their first HIV regimen, as well as those patients who have been treated in the past.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804401370\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876299\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=see_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"./kaposis-sarcoma-the-basics?source=see_link\">",
"      Patient information: Kaposi&rsquo;s sarcoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876307\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=see_link\">",
"      Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/19/37173?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Boosted protease inhibitor monotherapy studies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14774?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33682?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/5/10325?source=see_link\">",
"      Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/61/986?source=see_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link\">",
"      Factors affecting HIV progression",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"      HIV protease inhibitors",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16712?source=see_link\">",
"      Screening laboratory tests in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26313?source=see_link\">",
"      HIV and the older patient",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Treatment Information Service",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 448-0440",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hivatis.org/\">",
"      www.hivatis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       AIDS Clinical Trials Information Service (ACTIS)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 874-2572",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.actis.org/\">",
"      www.actis.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       <span class=\"nowrap\">",
"        HIV/AIDS",
"       </span>",
"       Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://aids.about.com/forum\">",
"      file://aids.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/31/15861/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/31/15861?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. www.AIDSinfo.nih.gov (Accessed on December 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15861/abstract/2\">",
"      Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_31_15861=[""].join("\n");
var outline_f15_31_15861=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIV TREATMENT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHO TREATS HIV?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHEN TO START HIV TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           PREPARING FOR HIV TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           HOW DO HIV MEDICATIONS WORK?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?32/60/33739\" title=\"table 1\">",
"           NNRTIs PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?5/17/5405\" title=\"table 2\">",
"           Protease inhibitors PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?11/5/11357\" title=\"table 3\">",
"           NRTIs PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15862="RML atelectasis PA";
var content_f15_31_15862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right middle lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA view of right middle lobe atelectasis in which the right cardiac border is obscured. Other findings include a faint increase in opacity in the right lower lung and a slight reduction in the overall right lung volume when compared with the left lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15862=[""].join("\n");
var outline_f15_31_15862=null;
var title_f15_31_15863="Neuroprotective therapy for Parkinson disease";
var content_f15_31_15863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuroprotective therapy for Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15863/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15863/contributors\">",
"     Daniel Tarsy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15863/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15863/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15863/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15863/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/31/15863/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic treatment of Parkinson disease (PD) can be divided into neuroprotective and symptomatic therapy. In practice, however, nearly all of the available treatments are symptomatic in nature and do not appear to slow or reverse the natural course of the disease.",
"   </p>",
"   <p>",
"    This topic will review potential neuroprotective therapies for PD. Other aspects of PD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link\">",
"     \"Etiology and pathogenesis of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroprotective therapy of PD is still theoretical, but it is based on the concept that the three to four hundred thousand at-risk dopaminergic neurons in the human substantia nigra can somehow be protected from the complex degenerative process that causes premature cell death and depletion of dopamine. Once identified and shown to be effective, neuroprotective drugs could be used in patients with early clinical signs of disease or potentially even prior to the appearance of disease in those shown to be at genetic risk.",
"   </p>",
"   <p>",
"    Several potential neuroprotective agents for PD have shown some promise in animals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    humans and are undergoing further investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     Selegiline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    (both monoamine oxidase inhibitors), dopamine agonists, and the complex I mitochondrial fortifier coenzyme Q10 have been evaluated in clinical trials and are receiving the most attention as possible neuroprotective agents.",
"   </p>",
"   <p>",
"    Our suggested approach for patients with newly diagnosed PD is to make them aware that much of the current therapeutic research in PD involves a search for neuroprotective agents; this gives them hope. To date, however, only weak signals have emerged for a few agents, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    and coenzyme Q10 appearing to be the most promising of these. After this discussion, some patients with early PD do elect&nbsp;treatment with one or both of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LEVODOPA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating clinical trial data suggest that levodopa either slows the progression of PD or has a prolonged benefit even after the drug has been stopped. These data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Levodopa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American Academy of Neurology (AAN) practice parameter concluded that levodopa is possibly neuroprotective for at least nine months and does not accelerate disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAO B INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoamine oxidase (MAO B) inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    have been studied as neuroprotective agents due to their ability to block free radical formation from the oxidative metabolism of dopamine; these agents may also inhibit apoptosis (programmed cell death) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to a possible neuroprotective effect, rasagiline and selegiline have a mild symptomatic benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rasagiline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selective MAO B inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    has neuroprotective properties in animal models. However, human trials have yielded inconsistent findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short-term randomized controlled trial (TEMPO) published in 2004 suggested that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      could slow progression of parkinsonian disability [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/7\">",
"       7",
"      </a>",
"      ]. Using a delayed start design, the trial found that patients assigned to early treatment with rasagiline monotherapy had a smaller increase in mean adjusted total Unified Parkinson Disease Rating Scale (UPDRS) score (",
"      <a class=\"graphic graphic_table graphicRef68974 \" href=\"UTD.htm?33/46/34530\">",
"       table 1",
"      </a>",
"      ) than those who were initially assigned to placebo for six months before starting rasagiline [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/7\">",
"       7",
"      </a>",
"      ]. However, the symptomatic benefit of rasagiline, rather than a neuroprotective effect, may have been responsible for this result [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In an open-label extension of the TEMPO trial with 6.5 years of follow-up published in 2009, the group assigned to earlier initiation of rasagiline showed a statistically significant slower progression of PD, as measured by the UPDRS score [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/8\">",
"       8",
"      </a>",
"      ]. This finding could be interpreted to support a neuroprotective or disease modifying effect of rasagiline. Alternatively, it might reflect an effect on endogenous compensatory mechanisms in early PD, such that the early introduction of any symptomatic treatment for PD results in a better clinical outcome than delayed administration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/9\">",
"       9",
"      </a>",
"      ]. The extension study must be interpreted very cautiously because of its open-label design, high (approximately 50 percent) drop-out rate, and statistical methodology that did not account for missing data due to loss of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ADAGIO trial also used a delayed start design to evaluate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      at two doses (1 mg and 2 mg daily) in 1176 subjects with untreated PD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/10\">",
"       10",
"      </a>",
"      ]. The group assigned to early start with rasagiline 1 mg daily met all prespecified criteria for a possible disease-modifying effect of rasagiline. However, the group assigned to early start with rasagiline 2 mg did not, because the change in total UPDRS score between baseline and week 72 was not significantly different compared with the 2 mg late start group. Thus, the two different doses were associated with different outcomes, and the overall trial results are inconclusive regarding a possible neuroprotective effect of rasagiline.",
"      <br/>",
"      <br/>",
"      A subsequent analysis of the ADAGIO trial found that, compared with placebo, both rasagiline 1 mg and 2 mg daily delayed the need for additional symptomatic antiparkinsonian medications [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/11\">",
"       11",
"      </a>",
"      ]. However, this outcome currently remains unsettled and may be explained by the known symptomatic effect of rasagiline and other monoamine oxidase B inhibitors for improvement of PD symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006 AAN practice parameter concluded that there is insufficient evidence to support or refute the use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     rasagiline",
"    </a>",
"    for neuroprotection in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ]. This conclusion remains valid despite the additional data from the 2009 TEMPO extension study and the 2009 ADAGIO trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2432865\">",
"    <span class=\"h2\">",
"     Selegiline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of long-term neuroprotection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    has neither been confirmed nor disproven:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large prospective, double-blind, placebo-controlled multicenter study (the DATATOP study) found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      (deprenyl) 10 mg daily delayed the progression of parkinsonian signs in previously untreated patients by nine months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/12\">",
"       12",
"      </a>",
"      ]. However, a small but measurable reduction of parkinsonian symptoms attributable to selegiline confounded the findings of this study, thereby casting doubt on the likelihood that the delayed progression of symptoms was due to a true neuroprotective effect.",
"     </li>",
"     <li>",
"      A subsequent trial that took this symptomatic effect into account noted a mild neuroprotective effect [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       Selegiline",
"      </a>",
"      treatment of patients with early Parkinson disease (PD) in the absence of levodopa was associated with a decreased risk for developing later freezing of gait [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/14\">",
"       14",
"      </a>",
"      ], suggesting a possible neuroprotective effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    in the DATATOP cohort did not reduce the occurrence of subsequent levodopa-associated motor fluctuations in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/15\">",
"     15",
"    </a>",
"    ]; no persistent, long-term benefit in slowing the progression of PD was demonstrated with selegiline.",
"   </p>",
"   <p>",
"    This lack of long-term benefit in part accounted for the conclusion issued in a 2002 report of the Quality Standards Subcommittee of the American Academy of Neurology (AAN) that there is insufficient evidence to recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    for a neuroprotective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/16\">",
"     16",
"    </a>",
"    ]. A practice parameter from the AAN issued in 2006 found no interim studies that would alter this conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DOPAMINE AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopamine agonists are neuroprotective in the laboratory because they are antioxidants and free radical scavengers and because of feedback reduction of endogenous dopamine turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. These findings have led to the hypothesis that the use of agonists early in the clinical course of PD may slow progression of the underlying neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Later studies employing radiographic markers of basal ganglia function, although highly controversial, have provided further, tentative support for a possible neuroprotective effect of dopamine agonists.",
"   </p>",
"   <p>",
"    One potential biologic marker uses single photon emission computed tomography (SPECT) with the dopamine transporter ligand [123I]beta-CIT (B-CIT) as an anatomic measure of nigrostriatal integrity and as a surrogate marker of PD progression. Earlier investigations of the natural history of PD had shown a 5 to 10 percent reduction of B-CIT uptake per year in a heterogeneous mix of patients with PD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pramipexole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CALM-PD study evaluated 82 patients with early PD, using SPECT B-CIT scans as a surrogate marker of neuroprotection, and found that the patients who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    (0.5 mg three times per day) demonstrated less of a decline in striatal B-CIT uptake over four years compared with those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    <span class=\"nowrap\">",
"     (25/100",
"    </span>",
"    mg three times per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/19\">",
"     19",
"    </a>",
"    ]. There was no difference between the two treatment groups for the change in the UPDRS scores (",
"    <a class=\"graphic graphic_table graphicRef68974 \" href=\"UTD.htm?33/46/34530\">",
"     table 1",
"    </a>",
"    ) from baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ropinirole",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial studied 162 patients eligible for analysis who were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    or levodopa treatment, using positron emission tomography (PET) scanning and the dopa decarboxylase ligand 18F-fluorodopa ((18)F-dopa) as a measure of nigrostriatal integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/20\">",
"     20",
"    </a>",
"    ]. There was significantly less decline in (18)F-dopa uptake in patients assigned to ropinirole compared with those assigned to levodopa.",
"   </p>",
"   <p>",
"    Another randomized trial employing (18)F-dopa PET as a surrogate marker of neuroprotection studied 45 patients who were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    or levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/21\">",
"     21",
"    </a>",
"    ]. At two years, the ropinirole treatment group showed a smaller reduction in the primary endpoint of putaminal (18)F-dopa uptake compared with placebo, but the difference was not statistically significant (13 versus 18 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether these imaging studies reflect changes in the underlying pathology of PD or differential pharmacologic \"regulatory\" changes directly attributable to the drugs themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/22\">",
"     22",
"    </a>",
"    ]. Therefore, these findings raise the possibility that dopamine agonists are neuroprotective, but confirmation is required in additional clinical studies, including prospective data in untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/3,23\">",
"     3,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006 AAN practice parameter noted that significance of the studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    is uncertain, given the lack of validation for the surrogate measures of neuroprotection employed (ie, SPECT B-CIT and (18)F-dopa PET scans) and the absence of placebo control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ]. The AAN concluded that there is insufficient evidence to support or refute the use of pramipexole or ropinirole for neuroprotection in patients with PD.",
"   </p>",
"   <p>",
"    Other clinical data argue against a neuroprotective effect of dopamine agonists [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/24\">",
"     24",
"    </a>",
"    ]. In a study reporting 14 year follow-up of patients who were enrolled in an early trial comparing the dopamine agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    with levodopa, initial treatment with bromocriptine did not reduce long-term mortality or motor disability, and the initial reduction in motor complications associated with bromocriptine was not sustained [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, there was no sustained benefit for early dopamine agonist treatment in a 15 year follow-up study of patients from another early trial comparing bromocriptine with levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in coenzyme Q10 has been stimulated by evidence that mitochondrial dysfunction may play a role in the pathogenesis of PD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and pathogenesis of Parkinson disease\", section on 'Mitochondrial dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a small clinical trial, 80 subjects with early untreated PD were randomly assigned to three dosage groups of coenzyme Q10 or to placebo, and were followed for progression of disease as measured by the Unified Parkinson Disease Rating Scale (UPDRS) (",
"    <a class=\"graphic graphic_table graphicRef68974 \" href=\"UTD.htm?33/46/34530\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/27\">",
"     27",
"    </a>",
"    ]. Treatment with coenzyme Q10 at the highest dosage (1200 mg daily) was associated with a lower rate of disability progression over 16 months compared with placebo. Although the results did not achieve statistical significance, they did meet the prespecified criteria for a positive trend for the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the study was underpowered to detect a neuroprotective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"     selegiline",
"    </a>",
"    , it is not entirely clear whether the benefit of coenzyme Q10 was due to neuroprotection or to symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/28\">",
"     28",
"    </a>",
"    ]; the study investigators considered the symptomatic effect of coenzyme Q10 to be negligible. In support of this opinion, a later randomized controlled trial of 131 patients with midstage PD found no symptomatic benefit at three months for coenzyme Q10 compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent futility analyses have been inconsistent regarding whether coenzyme Q10 warrants further study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/30\">",
"     30",
"    </a>",
"    ]. The 2006 AAN practice parameter concluded that there is insufficient evidence to support or refute the use of coenzyme Q10 for neuroprotection in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vitamin E",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the randomized controlled DATATOP trial of patients with early PD, Vitamin E (tocopherol) was included as a treatment arm [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/12\">",
"     12",
"    </a>",
"    ]. There was no beneficial effect of vitamin E compared with placebo for the primary end point of average time to onset of disability requiring levodopa use. Given these data, the 2006 AAN practice parameter concluded that vitamin E should not be considered for neuroprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Riluzole",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled trial of patients with early PD found no beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    compared with placebo as measured by change in the UPDRS (",
"    <a class=\"graphic graphic_table graphicRef68974 \" href=\"UTD.htm?33/46/34530\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/31\">",
"     31",
"    </a>",
"    ]. However, this study was not sufficiently powered to exclude a modest neuroprotective effect of riluzole [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Uric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uric acid (urate) has antioxidant properties, suggesting that it may prevent oxidative damage and cell death in PD. Data supporting this hypothesis are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several observational studies have shown that a high plasma uric acid concentration is associated with a reduced risk of developing PD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      One report of patients with early PD found that high plasma and cerebrospinal fluid uric acid levels at baseline were associated with a slower rate of clinical progression [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A large population-based study with a 14-year follow-up reported that dietary intake expected to increase plasma uric acid level is associated with a lower risk of PD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with a history of gout appear to have a lower risk of PD than those without gout [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonetheless, the finding of an association between uric acid concentration and the risk of PD does not prove that urate is neuroprotective. Furthermore, the therapeutic utility of urate (and diets designed to increase plasma uric acid) is likely to be limited by adverse effects with regard to the risk of developing gout and renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15863/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=see_link\">",
"       \"Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroprotective therapy of Parkinson disease (PD) is still theoretical, but it is based on the concept that dopaminergic neurons in the substantia nigra can be protected from the degenerative process that causes premature cell death and depletion of dopamine, leading to the development of PD. However, no treatment for PD has been proven to be neuroprotective. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While not established to be neuroprotective, levodopa is possibly neuroprotective and does not accelerate disease progression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacologic treatment of Parkinson disease\", section on 'Levodopa'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monoamine oxidase (MAO B) inhibitors such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25448?source=see_link\">",
"       selegiline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"       rasagiline",
"      </a>",
"      have been studied as neuroprotective agents due to their ability to block free radical formation from the oxidative metabolism of dopamine; these agents may also inhibit apoptosis. Dopamine agonists are neuroprotective in the laboratory because they are antioxidants and free radical scavengers and because of feedback reduction of endogenous dopamine turnover. Interest in coenzyme Q10 has been stimulated by evidence that mitochondrial dysfunction may play a role in the pathogenesis of PD. Nevertheless, existing clinical trial evidence in patients with PD is insufficient to support or refute the possibility of neuroprotection for MAO B inhibitors (selegiline, rasagiline), dopamine agonists (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/19/32055?source=see_link\">",
"       pramipexole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"       ropinirole",
"      </a>",
"      ), coenzyme Q10, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MAO B inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Dopamine agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Coenzyme Q10'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Riluzole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that Vitamin E is neuroprotective. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vitamin E'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/1\">",
"      Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003; 60:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/2\">",
"      Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/3\">",
"      LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology 2004; 63:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/4\">",
"      Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 2004; 63:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/5\">",
"      Hart RG, Pearce LA, Ravina BM, et al. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009; 24:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/6\">",
"      Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/7\">",
"      Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/8\">",
"      Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009; 24:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/9\">",
"      Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/10\">",
"      Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/11\">",
"      Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/12\">",
"      Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993; 328:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/13\">",
"      Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/14\">",
"      Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/15\">",
"      Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/16\">",
"      Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58:11.",
"     </a>",
"    </li>",
"    <li>",
"     Olanow, CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease. In: Dopamine Agonists in Early Parkinson's Disease, Olanow, CW, Obeso, JA (Eds), Wells Medical, Kent, UK 1997. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/18\">",
"      International symposium on early dopamine agonist therapy of Parkinson's disease. Arch Neurol 1988; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/19\">",
"      Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/20\">",
"      Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/21\">",
"      Rakshi JS, Pavese N, Uema T, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 2002; 109:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/22\">",
"      Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/23\">",
"      Albin RL, Frey KA. Initial agonist treatment of Parkinson disease: a critique. Neurology 2003; 60:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/24\">",
"      Weiner WJ, Reich SG. Agonist or levodopa for Parkinson disease?: ultimately, it doesn't matter; neither is good enough. Neurology 2008; 71:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/25\">",
"      Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/26\">",
"      Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/27\">",
"      Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/28\">",
"      Horstink MW, van Engelen BG. The effect of coenzyme Q10 therapy in Parkinson disease could be symptomatic. Arch Neurol 2003; 60:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/29\">",
"      Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007; 64:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/30\">",
"      NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/31\">",
"      Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002; 8:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/32\">",
"      Davis JW, Grandinetti A, Waslien CI, et al. Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol 1996; 144:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/33\">",
"      de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/34\">",
"      Weisskopf MG, O'Reilly E, Chen H, et al. Plasma urate and risk of Parkinson's disease. Am J Epidemiol 2007; 166:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/35\">",
"      Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/36\">",
"      Gao X, Chen H, Choi HK, et al. Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 2008; 167:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15863/abstract/37\">",
"      Alonso A, Rodr&iacute;guez LA, Logroscino G, Hern&aacute;n MA. Gout and risk of Parkinson disease: a prospective study. Neurology 2007; 69:1696.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4894 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15863=[""].join("\n");
var outline_f15_31_15863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LEVODOPA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAO B INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rasagiline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2432865\">",
"      Selegiline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DOPAMINE AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pramipexole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ropinirole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vitamin E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Riluzole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Uric acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4894|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/46/34530\" title=\"table 1\">",
"      Unified Parkinson Disease Rating Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=related_link\">",
"      Etiology and pathogenesis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28449?source=related_link\">",
"      Patient information: Parkinson disease treatment options &mdash; education, support, and therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15864="Vesiculobullous and pustular lesions in the newborn";
var content_f15_31_15864=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vesiculobullous and pustular lesions in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Josie A Pielop, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15864/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/31/15864/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicles, bullae, and pustules in the newborn may be caused by infections, congenital disorders, or other diseases. Benign and self-limited disorders, including erythema toxicum neonatorum (",
"    <a class=\"graphic graphic_picture graphicRef70785 \" href=\"UTD.htm?36/53/37713\">",
"     picture 1",
"    </a>",
"    ), transient neonatal pustular melanosis (",
"    <a class=\"graphic graphic_picture graphicRef59397 \" href=\"UTD.htm?35/14/36067\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64567 \" href=\"UTD.htm?21/33/22033\">",
"     picture 3",
"    </a>",
"    ), and neonatal acne (",
"    <a class=\"graphic graphic_picture graphicRef56615 \" href=\"UTD.htm?29/8/29829\">",
"     picture 4",
"    </a>",
"    ), do not require specific therapy. However, certain infections and genetic disorders must be differentiated from these self-limited conditions because treatment may be needed.",
"   </p>",
"   <p>",
"    Blistering conditions in the newborn caused by infection or congenital abnormalities are reviewed here. Benign neonatal vesiculopustular and bullous disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection always should be considered as a cause of vesiculobullous or pustular lesions in the newborn. Infectious disorders may be life-threatening and require urgent therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of viruses can cause vesiculopustular or bullous lesions in the newborn. In most cases, lesions do not appear at birth but rather days to weeks later. Herpes simplex virus (HSV) and varicella-zoster virus (VZV) are the two most common, but cytomegalovirus (CMV) and coxsackieviruses occasionally can induce these types of skin lesions. In the past, variola virus (smallpox) was also in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=see_link\">",
"     \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Herpes simplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal HSV infection primarily results from intrapartum exposure to maternal cervical or vaginal lesions, or by an ascending infection, sometimes through apparently intact membranes. Postnatal inoculation also may occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms can develop within days to four weeks after birth. HSV infection in newborns usually develops in one of three patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Localized to the skin, eyes, and mouth",
"     </li>",
"     <li>",
"      Localized central nervous system (CNS) disease",
"     </li>",
"     <li>",
"      Fulminant, disseminated disease involving multiple organs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin lesions occur in the majority of patients and may be present in all three patterns. The skin lesions typically consist of 1 to 3 mm vesicles and erythematous papules that may develop into pustules, crusts, and erosions (",
"    <a class=\"graphic graphic_picture graphicRef75059 \" href=\"UTD.htm?4/3/4159\">",
"     picture 5",
"    </a>",
"    ). They usually occur on the scalp (sometimes associated with placement of a fetal monitor electrode) or face [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/1\">",
"     1",
"    </a>",
"    ]. Lesions also may occur on the trunk or buttocks (especially with a breech presentation).",
"   </p>",
"   <p>",
"    Lesions are not usually present at birth, and develop at 6 to 13 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/1\">",
"     1",
"    </a>",
"    ]. In most cases, infants with lesions at birth that are suspicious for HSV have an intrauterine infection, in which case they usually also are premature, low birth weight, and microcephalic, or have another vesiculopustular disorder such as congenital candidiasis, transient pustular melanosis of the newborn (",
"    <a class=\"graphic graphic_picture graphicRef59397 \" href=\"UTD.htm?35/14/36067\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64567 \" href=\"UTD.htm?21/33/22033\">",
"     picture 3",
"    </a>",
"    ), or incontinentia pigmenti (",
"    <a class=\"graphic graphic_picture graphicRef58769 \" href=\"UTD.htm?12/38/12897\">",
"     picture 6",
"    </a>",
"    ). When lesions are present at birth, they usually appear as superficial erosions.",
"   </p>",
"   <p>",
"    Although most lesions in older children are self-limited, neonatal infections are more likely to disseminate. Newborns with disseminated disease often appear septic, with vascular instability, hepatic dysfunction, disseminated intravascular coagulation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory failure. CNS disease presents with fever, lethargy, and focal seizures.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, treatment, and prognosis of neonatal HSV infection are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=see_link\">",
"     \"Neonatal herpes simplex virus infection: Management and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Varicella-zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal varicella is a serious illness associated with a mortality rate up to 25 percent. Newborns born to mothers who are exposed to VZV or have clinical disease manifestations within two weeks of delivery are at the greatest risk for infection. Nosocomial acquisition of VZV also can occur. Varicella zoster infection in the newborn is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=see_link\">",
"     \"Varicella-zoster infection in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infection in neonates may present with vesiculobullous or pustular lesions. The most common organism to cause pustules accompanying neonatal sepsis is Staphylococcus aureus. Because up to 60 percent of infants become colonized in the first few weeks of life, this organism is also an important cause of superficial skin infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/2\">",
"     2",
"    </a>",
"    ]. Listeria monocytogenes, streptococcal species, Pseudomonas aeruginosa, Treponema pallidum, and Haemophilus influenzae type b are other etiologic bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Staphylococcal pyoderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. aureus can directly infect the skin, resulting in pyoderma that is characterized by pustules, erythematous papules, and honey-colored crusts. Lesions usually are found in areas of trauma, such as the diaper area, circumcision wound, axillae, and periumbilical skin, although they may appear anywhere on the body.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed with demonstration of Gram-positive cocci in clusters and neutrophils on Gram stain of the vesicular fluid and isolation of S. aureus on culture. If lesions are extensive or the infant appears ill, a blood culture should be obtained prior to starting treatment.",
"   </p>",
"   <p>",
"    The evaluation and treatment of S. aureus skin infection in the newborn infants are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=see_link&amp;anchor=H18#H18\">",
"     \"Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children\", section on 'Approach for children &le;30 days of age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Staphylococcal scalded skin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns are especially susceptible to dissemination of S. aureus exfoliative toxins, producing the staphylococcal scalded skin syndrome (SSSS or Ritter disease). The toxins act at the zona granulosa of the epidermis, causing cleavage of desmoglein 1 complex, an important protein in desmosomes, the organelles that help anchor keratinocytes to each other [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/3\">",
"     3",
"    </a>",
"    ]. This results in the formation of fragile, tense bullae that often are no longer intact by the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presentation usually occurs at 3 to 7 days of age, and is rarely seen at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected infants are febrile and irritable, with diffuse blanching erythema often beginning around the mouth. Flaccid blisters appear one to two days later, especially in areas of mechanical stress including flexural areas, buttocks, hands, and feet (",
"    <a class=\"graphic graphic_picture graphicRef50249 graphicRef72261 \" href=\"UTD.htm?42/31/43510\">",
"     picture 7A-B",
"    </a>",
"    ). Gentle pressure applied to the skin results in separation of the upper epidermis and wrinkling of the skin (Nikolsky's sign). In some cases, the entire upper epidermis may be shed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected infants often have conjunctivitis; mucous membranes are not involved but may appear hyperemic.",
"   </p>",
"   <p>",
"    Flaky desquamation occurs as the lesions heal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/1\">",
"     1",
"    </a>",
"    ]. Because the cleavage plane of the blisters is intraepidermal, scars do not occur.",
"   </p>",
"   <p>",
"    If SSSS is suspected, cultures should be obtained from blood, urine, nasopharynx, umbilicus, abnormal skin, or any suspected focus of infection. The intact bullae are sterile. Diagnosis is usually clinical, although may be confirmed with skin biopsy that shows a cleavage plane in the lower stratum granulosum with minimal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/5\">",
"     5",
"    </a>",
"    ]. However, biopsy is rarely required. The microscopic examination may be performed on a frozen section to expedite treatment.",
"   </p>",
"   <p>",
"    The biopsy will differentiate SSSS from toxic epidermal necrolysis (TEN), which is more commonly seen in adults or older children as a drug reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/6\">",
"     6",
"    </a>",
"    ]. Pathology specimens of TEN reveal a subepidermal cleavage plane and epidermal necrosis. Additionally, unlike SSSS, involvement of mucous membranes is a frequent clinical feature of TEN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of prompt administration of intravenous penicillinase-resistant penicillin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    . Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be considered in areas with a high prevalence of CA-MRSA or for patients who fail to respond to initial therapy, as SSSS secondary to MRSA infection has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment of neonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive skin care should be provided, with the use of emollients, such as creams or ointments, to improve barrier function. Fluid and electrolyte status should be monitored with losses replaced as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Streptococcal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal skin infections may mimic those caused by staphylococci, although they are less common. Epidemics of group A streptococcus (GAS) infections have been reported. Affected newborns may present with pustules and honey-colored crusts, often in association with a moist umbilical cord stump or omphalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group B streptococci (GBS) most commonly cause neonatal sepsis. However, skin lesions, such as bullae, erosions, and honey-colored crusts, occur rarely. Unlike other bacterial skin lesions, those resulting from GBS may be present at birth or develop later [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H11#H11\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If streptococcal disease is suspected, Gram stain and culture of a skin lesion should be obtained. Gram-positive cocci in chains will distinguish these from staphylococcal infections, although culture is necessary to distinguish GAS from GBS. Cultures of blood, urine, and CSF are obtained to rule out evidence of disseminated disease",
"   </p>",
"   <p>",
"    Treatment of GAS includes parenteral antibiotics and surveillance for evidence of invasive infection. For isolated GBS skin lesions, intramuscular penicillin (25,000 to 50,000 units every eight hours for 10 days) is adequate. If there is clinical or laboratory evidence of invasive infection, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    should be started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Listeriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections resulting from Listeria monocytogenes can present in newborns. Clinical manifestations can occur early, before seven days, or late, after seven days. Both forms can present with meningitis and signs of septicemia. Infants with the early form often have multiple pustules on the skin and mucous membranes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Congenital syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital syphilis occurs when the spirochete T. pallidum is transmitted from a pregnant woman to her fetus. It should always be included in the differential diagnosis of a newborn with blisters or erosions, especially when present at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809272#H28809272\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Early congenital syphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early manifestations can be quite variable. Infants may be normal at birth and become symptomatic during the first five weeks of life. Hemorrhagic bullae and petechiae that start on the palms and soles and spread to the trunk and extremities are nearly pathognomonic of congenital syphilis (",
"    <a class=\"graphic graphic_picture graphicRef81352 \" href=\"UTD.htm?40/53/41823\">",
"     picture 8",
"    </a>",
"    ). If ulcerative in nature, they are highly contagious. A more common presentation is a papulosquamous eruption similar to the exanthem of secondary syphilis in adults or a desquamative dermatitis also involving the palms and soles. Other early manifestations include rhinitis (snuffles), anemia, thrombocytopenia, lymphadenopathy, hepatomegaly, fever, and poor feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of congenital syphilis is discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809398#H28809398\">",
"     \"Congenital syphilis: Clinical features and diagnosis\", section on 'Approach to diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=see_link&amp;anchor=H21000446#H21000446\">",
"     \"Congenital syphilis: Evaluation, management, and prevention\", section on 'Evaluation and management of infants &lt;1 month of age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fungal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida albicans infections are common in the neonatal period and are usually benign. Case reports have been published of Aspergillus species causing vesicular lesions in very-low-birth-weight newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neonatal candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal candidiasis usually develops after the first week of life. It is most likely to affect moist, warm regions and skin folds, such as in the diaper area, or mucous membranes in the mouth, where it is known as thrush. Candidal diaper dermatitis characteristically appears as an erythematous rash in the inguinal region. The rash classically has areas of confluent erythema with multiple tiny pustules or discrete erythematous papules and plaques with superficial scales. Satellite lesions are typically noted (",
"    <a class=\"graphic graphic_picture graphicRef59361 graphicRef72165 \" href=\"UTD.htm?35/41/36501\">",
"     picture 9A-B",
"    </a>",
"    ). Topical treatment is adequate in most cases, as dissemination is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oropharyngeal candidiasis or thrush can manifest in several ways. The pseudomembranous form is the most common and appears as white plaques on the buccal mucosa, palate, tongue, or the oropharynx. Infants with thrush may be totally asymptomatic or may refuse to eat because of discomfort from the infection. Topical therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    ) is usually effective. In breastfeeding infants, the mother also may require treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of Candida infections in children\", section on 'Oropharyngeal candidiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Congenital candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital cutaneous candidiasis is a rare disorder that results from a Candida spp. infection acquired in utero or during delivery. The clinical manifestations and treatment of congenital candidiasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SCABIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scabies is an uncommon cause of eruptions in the developed world, but is common worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/14\">",
"     14",
"    </a>",
"    ]. The disorder is caused by infestation with the Sarcoptes scabiei mite. The skin eruption is because of a hypersensitivity reaction to the proteins of the female parasite, which burrows into the upper layers of the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/15\">",
"     15",
"    </a>",
"    ]. Transmission of scabies is usually from person to person by direct contact.",
"   </p>",
"   <p>",
"    Scabies may present as early as 3 to 4 weeks of age, the earliest time infants can develop hypersensitivity to the mites, and is never present at birth. The characteristic appearance is of erythematous papules that are intensely pruritic. Infants are more likely than older children to develop vesicles, pustules, and crusting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/16\">",
"     16",
"    </a>",
"    ]. The involvement usually is widespread, and often affects the hands, feet, and wrists, which usually are spared in older children and adults. The face may be involved because of contact with infested maternal skin while breastfeeding. Infants may manifest poor feeding, fussiness and failure to thrive, presumably because of the intense pruritus, or be asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis should be considered in an infant with a vesiculopustular eruption that involves the palms and soles (",
"    <a class=\"graphic graphic_picture graphicRef76789 \" href=\"UTD.htm?14/5/14416\">",
"     picture 10",
"    </a>",
"    ). It is often confused with infantile acropustulosis, insect bites, impetigo, or urticaria pigmentosa. The combination of a pruritic eruption, characteristic distribution, and family involvement is usually enough to establish a diagnosis. Mites or eggs can be demonstrated in scrapings from burrows or papules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"     \"Scabies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of one application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    5 percent cream at bedtime to all skin surfaces in infants and from the neck down in older family members; it should be washed off after 8 to 14 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/14\">",
"     14",
"    </a>",
"    ]. Repeated applications may be needed, as the failure rate is significant. Ten to 20 percent of patients require retreatment in 7 to 10 days because of persistent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/18\">",
"     18",
"    </a>",
"    ]. An alternative therapy for newborns is the application of 5 to 10 percent precipitated sulfur in petrolatum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CONGENITAL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many less-common genetic and sporadic conditions may produce vesiculopustular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bullous lesions in the newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa (EB) is a group of inherited diseases characterized by skin fragility and blister formation caused by minor skin trauma. EB is broadly classified into three groups by the level at which the blisters form. These are EB simplex, junctional EB, and dystrophic EB. Separation is at the intraepidermal, intra-lamina lucida, and sub-basal lamina levels, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"     \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of EB consists of prevention of trauma, careful wound care, and treatment of infection. More severe forms of EB, such as recessive dystrophic EB, require intensive palliative and supportive measures to address common complications such as pain, nutritional deficiencies, life-threatening infections, and debilitating deformities secondary to scarring of the skin and mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Epidermolytic hyperkeratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolytic hyperkeratosis (EHK), also known as bullous ichthyosis or bullous congenital ichthyosiform erythroderma, is an autosomal dominant disorder that typically presents in the neonatal period. Raw erosions are present at birth. Bullae, although not intact at birth, may continue to form throughout early childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H8#H8\">",
"     \"The genodermatoses\", section on 'Epidermolytic ichthyosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of a positive family history, EHK may be confused with EB. However, in contrast to EB, infants with EHK have generalized hyperkeratosis. Scaling and erythema become more prominent with age, although most blistering resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Aplasia cutis congenita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aplasia cutis congenita (ACC) is a group of heterogeneous diseases characterized by congenital focal absence of the skin. It is most often limited to a solitary midline posterior scalp lesion, but other presentations include several smaller scalp defects or involvement of the extremities or trunk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/20\">",
"     20",
"    </a>",
"    ]. Clinical subtypes are characterized by their location and pattern of lesions, associated malformations, and mode of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erosions are present at birth. Unlike other blistering disorders, ACC involves both epidermis and dermis. A typical lesion is a sharply demarcated ulcerated plaque or patch that may be covered by a tense epidermal membrane, giving the appearance of a fluid-filled bulla. The lesions reepithelialize over several months, resulting in a hypertrophic or atrophic scar [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/22\">",
"     22",
"    </a>",
"    ]. The differential diagnosis includes other neonatal blistering conditions, such as EB, and lesions secondary to perinatal trauma, including scalp blood sampling, fetal monitoring electrodes, and forceps.",
"   </p>",
"   <p>",
"    ACC is usually an isolated condition. However, other malformations may be associated. These include trisomy 13 or 4p- syndrome, cleft lip and palate, and defects of the hands and feet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/22\">",
"     22",
"    </a>",
"    ]. A subtype characterized by a ring of long dark hair surrounding a congenital scalp lesion (hair collar sign), may indicate an associated cranial neural tube defect such as an encephalocele, meningocele, or heterotopic brain tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/23\">",
"     23",
"    </a>",
"    ]. One proposed mechanism is that this may arise from an abnormality of separation of the epithelial and neural ectoderm at the time of neural tube closure.",
"   </p>",
"   <p>",
"    The etiology of ACC is uncertain, but it may result from a failure of ectodermal fusion during embryogenesis. This is supported by the observation that aplasia cutis of the face, which usually has a bilateral and preauricular location, appears to result from incomplete fusion of the ectodermal groove between the maxillary and mandibular facial prominences [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment usually consists of conservative wound care. Most lesions will reepithelialize spontaneously; larger lesions may require surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Incontinentia pigmenti",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incontinentia pigmenti (IP) is an X-linked dominant multisystem disease that is usually lethal in males. Skin lesions eventually develop in all patients. They are present at birth in approximately 50 percent of cases, and often are the only obvious neonatal finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H29839499#H29839499\">",
"     \"The genodermatoses\", section on 'Incontinentia pigmenti'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin lesions develop in four stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythematous papules and vesicles appear in crops in linear streaks along the lines of Blaschko, usually beginning at birth or within the first few weeks of life, with each crop lasting one to two weeks (",
"      <a class=\"graphic graphic_picture graphicRef78272 \" href=\"UTD.htm?31/60/32706\">",
"       picture 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The verrucous stage follows, consisting of hyperkeratotic warty papules or plaques in linear or swirling patterns (",
"      <a class=\"graphic graphic_picture graphicRef53297 \" href=\"UTD.htm?6/9/6292\">",
"       picture 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The third pigmented stage presents as streaks of hyperpigmentation in a \"marble cake pattern&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef63009 \" href=\"UTD.htm?34/9/34962\">",
"       picture 13",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The hyperpigmented streaks then may evolve into a final stage of hypopigmentation and atrophic patches or streaks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All stages may be present simultaneously, and may occur in utero.",
"   </p>",
"   <p>",
"    Other cutaneous changes include patchy alopecia, woolly-hair nevus, and nail dystrophy. Systemic abnormalities occur in nearly 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/25\">",
"     25",
"    </a>",
"    ]. These include dental abnormalities, ocular problems, neurologic complications, and other less frequent structural malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical diagnosis is confirmed with skin biopsy that demonstrates a spongiotic dermatitis with many eosinophils and large dyskeratotic cells during the vesicular stage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/28\">",
"     28",
"    </a>",
"    ]. This appearance differentiates it from similar lesions, such as erythema toxicum neonatorum, zosteriform HSV, and diffuse cutaneous mastocytosis. Molecular-based diagnosis is available by demonstrating mutations in NEMO (NF-kappaB essential modulator) that occur in 85 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15864/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Congenital sucking blisters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital sucking blisters are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H11#H11\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Sucking blisters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71166047\">",
"    <span class=\"h2\">",
"     Transient neonatal pustular melanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient neonatal pustular melanosis (",
"    <a class=\"graphic graphic_picture graphicRef59397 \" href=\"UTD.htm?35/14/36067\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64567 \" href=\"UTD.htm?21/33/22033\">",
"     picture 3",
"    </a>",
"    ) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H5#H5\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Transient neonatal pustular melanosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CUTANEOUS MASTOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mastocytosis is an infiltrative skin disorder that can present with blisters in the newborn (",
"    <a class=\"graphic graphic_picture graphicRef52257 \" href=\"UTD.htm?43/7/44145\">",
"     picture 14",
"    </a>",
"    ). The two main forms are urticaria pigmentosa (UP), which may consist of solitary or multiple lesions, and more rarely, diffuse cutaneous mastocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of diseases can cause vesicular or pustular eruptions on the skin of young infants. A thorough clinical history and physical exam provides important clues for diagnosis. The possibility of a viral, bacterial, or fungal infection should always be considered. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to local pyoderma, Staphylococcus aureus infection may cause staphylococcal scalded skin syndrome (SSSS). In SSSS, toxins produced by the organism induce cutaneous erythema, bullae, and desquamation. Microscopic examination of a frozen section of lesional skin is a quick method to distinguish this disorder from toxic epidermolytic necrolysis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Staphylococcal scalded skin syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythematous papules patches, papules, and pustules in intertriginous areas may occur in neonatal candidiasis. Satellite lesions are a frequent finding. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Neonatal candidiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scabies in infants can present with inflammatory vesicles",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pustules. Lesions may be widespread, and often involve the hands, wrists, and feet. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Scabies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link\">",
"       \"Scabies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vesicular lesions following the lines of Blaschko on a newborn infant suggest the possibility of incontinentia pigmenti, a rare, X-linked dominant disorder. Later stages of incontinentia pigmenti are characterized by verrucous papules and pigmentary alteration. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Incontinentia pigmenti'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An erosive patch or blister-like lesion on the scalp or another area of the body at birth may occur due to a local absence of skin called aplasia cutis congenita. Aplasia cutis congenita is occasionally associated with other physical defects or genetic disorders. A conspicuous collar of hair around a lesion on the scalp may indicate the presence of an underlying neurological defect. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Aplasia cutis congenita'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hoath, SB, Narendran, V. The skin. In: Neonatal-Perinatal Medicine, 9th Ed, Fanaroff, AA,  Martin , RJ, Walsh, MC (Eds), Elsevier Mosby, St. Louis 2011. p.1705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/2\">",
"      Speck WT, Driscoll JM, Polin RA, et al. Staphylococcal and streptococcal colonization of the newborn infant: effect of antiseptic cord care. Am J Dis Child 1977; 131:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/3\">",
"      Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 2003; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/4\">",
"      Ladhani S, Joannou CL, Lochrie DP, et al. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev 1999; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/5\">",
"      Elias PM, Fritsch P, Epstein EH. Staphylococcal scalded skin syndrome. Clinical features, pathogenesis, and recent microbiological and biochemical developments. Arch Dermatol 1977; 113:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/6\">",
"      Honig PJ, Gaisin A, Buck BE. Frozen section differentiation of drug-induced and staphylococcal-induced toxic epidermal necrolysis. J Pediatr 1978; 92:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/7\">",
"      Ito Y, Funabashi Yoh M, Toda K, et al. Staphylococcal scalded-skin syndrome in an adult due to methicillin-resistant Staphylococcus aureus. J Infect Chemother 2002; 8:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/8\">",
"      Chi CY, Wang SM, Lin HC, Liu CC. A clinical and microbiological comparison of Staphylococcus aureus toxic shock and scalded skin syndromes in children. Clin Infect Dis 2006; 42:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/9\">",
"      Isenberg HD, Tucci V, Lipsitz P, FAcklam RR. Clinical laboratory and epidemiological investigations of a Streptococcus pyogenes cluster epidemic in a newborn nursery. J Clin Microbiol 1984; 19:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/10\">",
"      Kline A, O'Donnell E. Group B streptococcus as a cause of neonatal bullous skin lesions. Pediatr Infect Dis J 1993; 12:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/11\">",
"      Dorfman DH, Glaser JH. Congenital syphilis presenting in infants after the newborn period. N Engl J Med 1990; 323:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/12\">",
"      Rowen JL, Atkins JT, Levy ML, et al. Invasive fungal dermatitis in the &lt; or = 1000-gram neonate. Pediatrics 1995; 95:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/13\">",
"      Perzigian RW, Faix RG. Primary cutaneous aspergillosis in a preterm infant. Am J Perinatol 1993; 10:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/14\">",
"      Nanda S, Reddy BS, Ramji S, Pandhi D. Analytical study of pustular eruptions in neonates. Pediatr Dermatol 2002; 19:210.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Scabies. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/16\">",
"      Quarterman MJ, Lesher JL Jr. Neonatal scabies treated with permethrin 5% cream. Pediatr Dermatol 1994; 11:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/17\">",
"      Hurwitz S. Scabies in babies. Am J Dis Child 1973; 126:226.",
"     </a>",
"    </li>",
"    <li>",
"     Meinking T, Taplin D. Infestations. In: Pediatric Dermatology, 2nd ed, Schachner LA, Hansen RC (Eds), Churchill Livingstone, New York 1995. p.1377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/19\">",
"      Rand RE, Baden HP. The ichthyoses--a review. J Am Acad Dermatol 1983; 8:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/20\">",
"      Fagan LL, Harris PA, Coran AG, Cywes R. Sporadic aplasia cutis congenita. Pediatr Surg Int 2002; 18:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/21\">",
"      Frieden IJ. Aplasia cutis congenita: a clinical review and proposal for classification. J Am Acad Dermatol 1986; 14:646.",
"     </a>",
"    </li>",
"    <li>",
"     Margileth AM. Dermatologic conditions. In: Neonatology, 5th ed, Avery GB, Fletcher MA, MacDonald MG (Eds), Lippincott Williams and Wilkins, Philadelphia 1999. p.1323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/23\">",
"      Drolet B, Prendiville J, Golden J, et al. 'Membranous aplasia cutis' with hair collars. Congenital absence of skin or neuroectodermal defect? Arch Dermatol 1995; 131:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/24\">",
"      Drolet BA, Baselga E, Gosain AK, et al. Preauricular skin defects. A consequence of a persistent ectodermal groove. Arch Dermatol 1997; 133:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/25\">",
"      Carney RG. Incontinentia pigmenti. A world statistical analysis. Arch Dermatol 1976; 112:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/26\">",
"      Cohen BA. Incontinentia pigmenti. Neurol Clin 1987; 5:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/27\">",
"      Francis JS, Sybert VP. Incontinentia pigmenti. Semin Cutan Med Surg 1997; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/28\">",
"      Cohen PR. Incontinentia pigmenti: clinicopathologic characteristics and differential diagnosis. Cutis 1994; 54:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15864/abstract/29\">",
"      Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11:2371.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5790 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15864=[""].join("\n");
var outline_f15_31_15864=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Herpes simplex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Varicella-zoster",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Staphylococcal pyoderma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Staphylococcal scalded skin syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Streptococcal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Listeriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Congenital syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fungal infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neonatal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Congenital candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SCABIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CONGENITAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Epidermolytic hyperkeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Aplasia cutis congenita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Incontinentia pigmenti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Congenital sucking blisters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71166047\">",
"      Transient neonatal pustular melanosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CUTANEOUS MASTOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5790\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5790|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/53/37713\" title=\"picture 1\">",
"      Erythema toxicum face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/14/36067\" title=\"picture 2\">",
"      Trans pustular melanosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/33/22033\" title=\"picture 3\">",
"      Transient neonatal pustular melanosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/8/29829\" title=\"picture 4\">",
"      Neonatal acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4159\" title=\"picture 5\">",
"      Neonatal HSV neck vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/38/12897\" title=\"picture 6\">",
"      Incontinentia pigmenti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44273\" title=\"picture 7A\">",
"      Staphylococcal scalded skin syndrome - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/52/13121\" title=\"picture 7B\">",
"      Staphylococcal scalded skin syndrome - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/53/41823\" title=\"picture 8\">",
"      Congenital syphilis rash on soles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/53/13136\" title=\"picture 9A\">",
"      Candidal diaper dermatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4945\" title=\"picture 9B\">",
"      Candidal diaper dermatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/5/14416\" title=\"picture 10\">",
"      Scabies infant foot 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/60/32706\" title=\"picture 11\">",
"      Incontinentia pigmenti 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/9/6292\" title=\"picture 12\">",
"      Incontinentia pigmenti 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/9/34962\" title=\"picture 13\">",
"      Incontinentia pigmenti 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44145\" title=\"picture 14\">",
"      Bullous eruption in SM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37049?source=related_link\">",
"      Congenital syphilis: Evaluation, management, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33290?source=related_link\">",
"      Evaluation and management of suspected methicillin-resistant Staphylococcus aureus skin and soft tissue infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40713?source=related_link\">",
"      Neonatal herpes simplex virus infection: Management and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=related_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15865="Selection of an umbilical cord blood graft for hematopoietic cell transplantation";
var content_f15_31_15865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15865/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/31/15865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2564267\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is an important and potentially curative treatment option for a wide variety of malignant and nonmalignant diseases. The pluripotent hematopoietic stem cells required for this procedure are usually obtained from the bone marrow or peripheral blood of a related or unrelated donor. Umbilical cord blood (UCB), the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an established alternative source of hematopoietic stem cells in allogeneic HCT.",
"   </p>",
"   <p>",
"    Engraftment and survival rates following HCT are optimized when the donor and recipient are genetically compatible. Human leukocyte antigen (HLA)-matched sibling donors are generally the preferred donor source for an allogeneic HCT. Unfortunately, finding an HLA-matched sibling is not always possible. Each full sibling potential donor has only a 25 percent chance of being fully HLA-matched with a sibling requiring a transplant. Therefore, most patients do not have an HLA-identical relative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H5#H5\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched related donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a suitable related donor is not available, a search is conducted to identify a potential unrelated HLA-matched donor. Finding an appropriate donor through a national registry is a lengthy process that is not always successful, especially for individuals who are not of Northern European descent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, the relative ease of procurement and the lower than anticipated risk of severe acute graft-versus-host disease has made unrelated UCB transplantation a possible alternative to unrelated donor bone marrow or mobilized peripheral blood progenitor cell transplant. The increased representation of ethnic minorities and the ability to use partially HLA-matched UCB units significantly expands the donor pool. In addition, the use of reduced-intensity or non-myeloablative preparative regimens to allow engraftment of UCB broadens the scope of patients who may benefit from allogeneic HCT, including elderly and medically infirm patients without an HLA-matched sibling donor.",
"   </p>",
"   <p>",
"    The advantages and limitations of UCB and the selection of an umbilical cord blood graft are discussed here. Other issues related to UCB are discussed separately, including the use of UCB transplantation in adults using myeloablative and non-myeloablative preparative regimens, and the collection, storage, and ethical issues regarding the use of UCB for HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604465\">",
"    <span class=\"h1\">",
"     CORD BLOOD AS A RESOURCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been significant advances in understanding the biological characteristics of UCB, in parallel with its applications in clinical transplantation. The success of the first allogeneic UCB transplantation in October 1988 in a child with Fanconi anemia paved the way for the use of UCB as a source of hematopoietic stem and progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/1\">",
"     1",
"    </a>",
"    ]. UCB banks have been established for related and unrelated UCB transplant with several hundred thousand units available in more than 50 cord blood banks worldwide (",
"    <a class=\"external\" href=\"file://www.bmdw.org/\">",
"     www.bmdw.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Procedures and quality standards for the safe collection, processing, testing, storage, selection, exchange, and clinical use of UCB are provided by NetCord-Foundation for the Accreditation of Cellular Therapy (",
"    <a class=\"external\" href=\"file://www.factwebsite.org/\">",
"     NetCord-FACT",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604472\">",
"    <span class=\"h2\">",
"     Demand for cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid expansion in the use of UCB for transplantation is the culmination of several factors, most of which serve to address the limitations encountered in the use of HLA-matched unrelated hematopoietic stem cells. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of suitable HLA-matched donors &mdash; Most patients do not have an HLA-identical relative since each full sibling potential donor has only a 25 percent chance of being fully HLA-matched with a sibling requiring a transplant. When a related donor is unavailable, a search for a matched unrelated donor",
"      <span class=\"nowrap\">",
"       (9/10",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      high resolution HLA match) is approximately 80 percent for individuals of Northwestern European descent and much lower for other ethnic groups [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Donor attrition &mdash; Despite the maintenance of large lists of volunteer donors worldwide, a significant percentage of donors will no longer be available for donation when needed.",
"     </li>",
"     <li>",
"      Time constraints &mdash; The process of identifying, typing, and harvesting an unrelated donor is cumbersome and lengthy, with the median time interval between initiation of a search and the donation of marrow of about four months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Graft-versus-host disease (GVHD) &mdash; Complications of GVHD are associated with HLA disparities, particularly if bone marrow from an unrelated donor is utilized [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/6-8\">",
"       6-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these issues is at least partially addressed by the use of unrelated UCB banks as described in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604479\">",
"    <span class=\"h2\">",
"     Advantages and limitations of cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrelated UCB offers many practical advantages over unrelated donor bone marrow (BM) or mobilized peripheral blood progenitor cells (PBPC) as a source of hematopoietic stem cells. However, challenges remain, particularly with the need to improve the rates of engraftment and enhance recovery of immune function following UCB transplantation (UCBT).",
"   </p>",
"   <p>",
"    Advantages of unrelated UCB include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expanded donor pool &mdash; The increased representation of ethnic minorities in the unrelated UCB banks and the ability to use partially HLA-matched UCB units significantly expands the donor pool [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H61604493\">",
"       'HLA type'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ease of procurement and lack of donor attrition &mdash; UCB can be substantially tested prior to storage for infections, blood and HLA-type, and cell dose, thereby making the samples more rapidly available for use [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/9\">",
"       9",
"      </a>",
"      ]. Likewise, the storage of UCB avoids the risk of donor attrition. Together, these characteristics result in a considerably faster time to UCBT than that seen with an unrelated BM or PBPC graft [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=see_link\">",
"       \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Graft-versus-host disease (GVHD) &mdash; Despite the infusion of HLA class I and II disparate grafts, the incidence and severity of acute and chronic GVHD among unrelated UCB recipients has thus far been lower than previously reported in recipients of matched unrelated donor marrow or partially-matched family member marrow allograft [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link&amp;anchor=H426440357#H426440357\">",
"       \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\", section on 'Graft-versus-host disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Safety for donors and recipients &mdash; UCB is relatively easy to collect after the delivery of a newborn and does not put the mother or newborn at risk. In addition, there is a reduced likelihood of transmitting infections (eg, cytomegalovirus) from the donor to the recipient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main limitations of UCB as a hematopoietic stem cell source are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased risk of graft failure &mdash; UCB contains limited numbers of hematopoietic progenitors and outcomes after transplant correlate with cell dose as a function of the recipient&rsquo;s body weight [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. As such, single UCB samples frequently do not contain sufficient hematopoietic progenitor cells to allow for the reconstitution of the bone marrow of a large child or adult. (See",
"      <a class=\"local\" href=\"#H61604500\">",
"       'Cell dose'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Delayed immune reconstitution &mdash; Infectious complications are common after UCBT, largely due to a delay in the time to neutrophil recovery and delayed acquired immune reconstitution [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/14\">",
"       14",
"      </a>",
"      ]. When compared with transplants of unrelated donor bone marrow or mobilized peripheral blood progenitor cells, UCBT is associated with a longer median duration of neutropenia (approximately 30 versus 14 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/15\">",
"       15",
"      </a>",
"      ]. However, there does not appear to be an increase in infection-related death. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link&amp;anchor=H426439939#H426439939\">",
"       \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\", section on 'Toxicity and transplant-related mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unavailability of the donor for additional donations (eg, donor lymphocyte infusions or other cell-based therapies)",
"     </li>",
"     <li>",
"      Possibility of transmitting undetected hematologic pathologies &mdash; Even though UCB samples are evaluated with a blood film and hemoglobinopathy screening prior to storage, there remains a theoretically increased risk of transmitting undetected hematologic diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autoimmune disorders &mdash; Although the incidence of GVHD appears to be lower than that seen with other sources of hematopoietic stem cells, the cumulative incidence of developing a new autoimmune disease appears to be at least as high following UCBT as following transplant of stem cells from other sources. A retrospective analysis of 778 patients who received UCBT between 1992 and 2008 reported cumulative incidence rates of autoimmune disease of 5 and 7 percent at one and five years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/16\">",
"       16",
"      </a>",
"      ]. The most common autoimmune disorders were autoimmune hemolytic anemia (20 patients), immune thrombocytopenia (11 patients), and Evans Syndrome (9 patients). The incidence was higher among patients transplanted for non-malignant diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    UCBT from a related or unrelated donor is a well accepted hematopoietic source in pediatric patients with hematologic malignancies, marrow failure, or metabolic syndromes; but in adults, there remain concerns about engraftment and immune reconstitution. The known limited numbers of hematopoietic progenitors and the correlation of cell dose with outcome make its use in adults more problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Furthermore, the majority of reported UCBT involved the use of myeloablative preparative regimens that are known to be associated with considerable morbidity and mortality. Despite having suitable UCB donors, many older patients and patients with co-morbidities will be precluded from receiving UCBT because of the unacceptable toxicities from the standard conditioning regimens. Methods to overcome these two concerns led to the studies of combined cord blood units and the use of non-myeloablative preparative regimens described in more detail below. (See",
"    <a class=\"local\" href=\"#H61604507\">",
"     'Combined cord blood units'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link&amp;anchor=H1254202#H1254202\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\", section on 'Non-myeloablative preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604486\">",
"    <span class=\"h1\">",
"     CORD BLOOD UNIT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main criteria for selecting umbilical cord blood (UCB) unit(s) for transplantation are the human leukocyte antigen (HLA) haplotype and the cryopreserved total nucleated cell dose per kilogram recipient body weight. Outside the setting of a clinical trial, an acceptable approach is to choose UCB units with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The closest HLA match &mdash;",
"      <span class=\"nowrap\">",
"       &ge;4/6",
"      </span>",
"      HLA match (HLA-A, -B, -DRB1) or",
"      <span class=\"nowrap\">",
"       &ge;4/8",
"      </span>",
"      match (HLA-A, -B, -C, -DRB1) (see",
"      <a class=\"local\" href=\"#H61604493\">",
"       'HLA type'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Adequate cell dose &mdash; &ge;3 x 10",
"      <sup>",
"       7",
"      </sup>",
"      nucleated",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      or &ge;2 x 10",
"      <sup>",
"       5",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H61604500\">",
"       'Cell dose'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there",
"    <sup>",
"    </sup>",
"    is no single unit with",
"    <sup>",
"    </sup>",
"    these characteristics then two units",
"    <sup>",
"    </sup>",
"    with a combined total",
"    <sup>",
"    </sup>",
"    dose of &ge;3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    and, if possible, not",
"    <sup>",
"    </sup>",
"    more than one HLA difference",
"    <sup>",
"    </sup>",
"    between the two units and the patient may be acceptable. Many centers preferentially use double cord units for transplantation. Each unit used for double UCBT should have a cell dose &gt;2 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg.",
"    </span>",
"    In patients without malignant disease, the cell doses should be higher or the HLA incompatibility lower. (See",
"    <a class=\"local\" href=\"#H61604507\">",
"     'Combined cord blood units'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some centers identify and reserve a &ldquo;backup graft&rdquo; to be used in the case of unexpected problems with the selected UCB unit when it thaws or if it fails to engraft [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/17\">",
"     17",
"    </a>",
"    ]. In such settings, a unit is reserved at the UCB bank (but not shipped) until the patient has engrafted. After engraftment, the reservation is cancelled and the &ldquo;backup graft&rdquo; can be reserved for another patient. Although controversial, the collection of autologous hematopoietic progenitor cells as a &ldquo;backup graft&rdquo; for patients at higher risk of graft failure does not appear to be necessary, especially in patients with a 6 of 6 HLA-match who are undergoing myeloablative UCB transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604493\">",
"    <span class=\"h2\">",
"     HLA type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matching donor and recipient for human leukocyte antigen (HLA) class I (-A, -B, and &ndash;C) and class II (-DRB1 and &ndash;DQ) haplotypes is a key part of successful allogeneic hematopoietic cell transplantation (HCT). Among patients undergoing unrelated donor bone marrow (BM) or mobilized peripheral blood progenitor cell (PBPC) HCT, there is a progressive decrease in post-HCT survival with each HLA allele mismatch [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/19\">",
"     19",
"    </a>",
"    ]. In this setting, molecular typing of 10 HLA alleles is preferred by most centers and acceptable donors are generally limited to no more than a single HLA mismatch. Initial studies suggested that the relative immaturity of the immune system in UCB samples allows for the crossing of immunologic barriers that would otherwise be prohibitive. Even so, HLA-matching is one of the most important factors in UCB unit selection and the best HLA-matched unit(s) is preferred. The importance of matching for KIR ligand status and HLA matching between UCB units in the setting of double UCB transplant is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike in the setting of unrelated donor BM or PBPC HCT, most UCB banks evaluate UCB samples using serologic testing for HLA-A and HLA-B and molecular typing for HLA-DRB1. Using this method, units that are matched at 4, 5, or 6 of 6 HLA alleles are potentially acceptable sources. UCB units with HLA-disparities equal to 3 of 6 or fewer are",
"    <strong>",
"     not",
"    </strong>",
"    acceptable since transplantation of such units results in high treatment related mortality (TRM) and low rates of disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. When available, additional matching for HLA-C improves patient outcomes.",
"   </p>",
"   <p>",
"    The importance of HLA-matching of UCB was best demonstrated in a retrospective analysis of 803 patients with leukemia or myelodysplastic syndrome who received an unrelated UCBT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of TRM was increased for patients mismatched at two (hazard ratio [HR] 3.27, 95% CI 1.42-7.54), three (HR 3.34, 95% CI 1.4-7.71), or four (HR 3.51, 95% CI 1.44-8.58) loci when compared with patients who were fully matched at 8 loci. There was no significant difference in TRM among patients mismatched at two, three, or four loci.",
"     </li>",
"     <li>",
"      Among patients matched for HLA-A, -B, and -DRB1, patients mismatched for HLA-C had higher TRM than those matched for HLA-C (HR 3.97, 95% CI 1.27-12.40). Mismatching for HLA-C also increased TRM among transplantations already mismatched at a single HLA-A, -B, or &ndash;DRB1 locus.",
"     </li>",
"     <li>",
"      Similarly, mismatching for HLA-DRB1 increased TRM among patients mismatched at a single HLA-A, -B, or &ndash;C locus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another retrospective comparison of the outcomes of 503 children with acute leukemia given an unrelated mismatched",
"    <sup>",
"    </sup>",
"    UCBT with 282 children with acute leukemia who received an unrelated BM transplant (116 HLA allele",
"    <sup>",
"    </sup>",
"    matched 8 out of 8) after a myeloablative preparative regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/22\">",
"     22",
"    </a>",
"    ]. The following outcomes were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA-mismatched BM recipients had",
"      <sup>",
"      </sup>",
"      more acute and chronic graft-versus-host disease (GVHD) without decreasing leukemia-free",
"      <sup>",
"      </sup>",
"      survival (LFS).",
"     </li>",
"     <li>",
"      LFS at five years was higher in children who received 6 of 6 (HLA-A,-B,-DRB1) matched UCBTs than in children who received 8 of 8 (HLA-A,-B,-C,-DRB1) matched BM transplants (60 versus 38 percent).",
"     </li>",
"     <li>",
"      There was a statistically nonsignificant trend toward decreasing LFS at five years with increasing UCB HLA-disparity being 60, 36 to 40, and 33 percent in children who received 6 of 6, 5 of 6 (with low or high cell dose), and 4 of 6 HLA-matched UCBT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that UCB units matched for 4, 5, or 6 of 6 HLA haplotypes produce results that are at least equal to an 8 of 8 HLA-matched BM HCT in children with malignancy. They also suggest that increased UCB cell dose may partially compensate for the negative impact of increasing HLA-disparity. Similar results were noted in a retrospective study of 1525 adults who underwent HCT for acute leukemia, 165 of whom received UCBT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients who received 4, 5, or 6 of 6 HLA-matched UCB had similar LFS rates to those who received 8 of 8 HLA-matched BM or PBPCs. Although treatment related mortality was higher among those receiving an UCBT, rates of acute and chronic GVHD were lower than after BM or PBPC transplantation.",
"   </p>",
"   <p>",
"    The direction of the HLA allele mismatch also appears to affect the rate of engraftment and the strength of a graft-versus-tumor effect. A retrospective analysis of 1202 recipients of a single cord blood unit transplant analyzed the outcomes among 98",
"    <span class=\"nowrap\">",
"     donor/recipient",
"    </span>",
"    pairs that had unidirectional mismatches only [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/24\">",
"     24",
"    </a>",
"    ]. The 58 patients with unidirectional mismatches in the graft-versus-host direction had significantly faster rates of engraftment. Patients in this subset who had hematologic malignancies also demonstrated rates of treatment failure, transplant-related mortality, and overall mortality that were similar to those seen with matched cord blood units. In contrast, patients with unidirectional mismatches in the host-versus-graft direction had slower engraftment, higher rates of graft failure, and higher relapse rates. Another study demonstrated increased rates of graft failure, treatment-related mortality, and inferior survival among patients receiving double UCB with mismatches in the host-versus-graft direction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When evaluating potential UCB units for selection, efforts should be made to choose the unit(s) with the greatest similarity in HLA haplotype to the recipient. If an 8 of 8 HLA matched unit is not available, an at least 4 of 8 HLA-matched unit is an acceptable alternative. Priority is given to unidirectional mismatches in the graft-versus-host direction and mismatches in the host-versus-graft direction are avoided, if possible. Other issues related to HLA matching of UCB include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA-C haplotype &mdash; Initial studies of UCB did not consider the HLA-C haplotype in the selection of UCB due to initial studies that suggested no impact of HLA-C matching on outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/26\">",
"       26",
"      </a>",
"      ]. Subsequently, the importance of HLA-C matching was demonstrated in a database study of 803 recipients of UCB [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/21\">",
"       21",
"      </a>",
"      ]. Among patients matched for HLA-A,-B, and -DRB1, patients mismatched for HLA-C had greater transplant related mortality than those matched for HLA-C (hazard ratio 3.97, 95% CI 1.27-12.40). Efforts should be made to select the UCB unit with the greatest HLA compatibility at HLA-A, HLA-B, HLA-C, and HLA-DRB1.",
"     </li>",
"     <li>",
"      Unit to unit matching &mdash; Experts differ in their approach towards matching UCB units in the setting of double UCBT. While some suggest that UCB units should be at least 3 of 6 HLA-matched to each other [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/14\">",
"       14",
"      </a>",
"      ], others do not place limits on unit to unit HLA-matching because retrospective analyses have not demonstrated a relationship between unit to unit HLA-matching and the likelihood of sustained donor engraftment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/17,27\">",
"       17,27",
"      </a>",
"      ]. Further studies need to be done to determine if we can forgo with the standard matching of units with other units in fear of the second unit rejecting the first. &nbsp;",
"     </li>",
"     <li>",
"      KIR gene &mdash; The killer-cell immunoglobulin-like receptor (KIR) gene encodes natural killer cell immunoglobulin-like receptors that recognize epitopes of HLA-A, HLA-B, and HLA-C, which are also called KIR ligands. Initial reports suggest that the donor&rsquo;s KIR gene haplotype may influence transplant outcomes in matched unrelated donors. The impact of KIR ligand status on UCBT is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H21756795#H21756795\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'KIR gene haplotype'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient HLA antibodies &mdash; Patients are not routinely screened for HLA antibodies prior to transplantation. However, if this information is available, HLA-mismatched units that contain HLA determinants for which the patient has preformed HLA antibodies should be avoided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a UCB unit has been selected for transplantation it is critical that the HLA-typing be confirmed on an attached or contiguous segment of the product. The importance of confirmatory HLA-typing was illustrated by a study that reported that 2 of 871 UCB units (0.2 percent) sent to a single medical center for HCT were mislabeled and potentially would have been transplanted incorrectly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604500\">",
"    <span class=\"h2\">",
"     Cell dose",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4260919\">",
"    <span class=\"h3\">",
"     Importance of cell dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the ideal cell dose for UCB transplantation (UCBT) is not known, it is clear that clinically important outcomes, including the incidence of graft failure and speed of bone marrow recovery, correlate with total nucleated cell (TNC) dose as a function of the recipient&rsquo;s body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Higher TNC doses are required for engraftment of UCB units with higher degrees of HLA-disparity. Actual recipient body weight is used rather than ideal or adjusted body weight. All UCB units should have a TNC dose measured prior to cryopreservation; however, progenitor cell measurements are not standardized between UCB banks. Such standardization may assist in selecting the appropriate unit. Although less commonly provided, a measure of CD34+ cells may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/29\">",
"     29",
"    </a>",
"    ]. Single UCB units require &ge;3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    or &ge;2 x 10",
"    <sup>",
"     5",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    for successful engraftment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/20\">",
"     20",
"    </a>",
"    ]. If two UCB units are used, each individual unit should have &ge;2.0 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H61604507\">",
"     'Combined cord blood units'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The importance of cell dose has been illustrated in several retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/22,29-31\">",
"     22,29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest was an analysis of 1061 patients who received a single-unit myeloablative UCBT for leukemia or myelodysplasia that evaluated the relative effects of HLA-match and TNC dose [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/20\">",
"       20",
"      </a>",
"      ]. Transplant-related mortality (TRM) increased sequentially for patients with decreasing TNC dose and increasing HLA-disparity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TRM was lowest for 6 of 6 HLA-matched units, regardless of TNC dose.",
"     </li>",
"     <li>",
"      Similar TRM rates were seen for patients who received either a 5 of 6 HLA-matched unit with a TNC between 2.5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg and 5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg or a 4 of 6 HLA-matched unit with a TNC of &ge;5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg.",
"     </li>",
"     <li>",
"      Higher TRM rates were seen for patients who received a 4 of 6 HLA-matched unit with a TNC between 2.5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg and 5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg.",
"     </li>",
"     <li>",
"      The highest TRM rates were seen for patients who received a unit with TNC &lt;2.5 x 10",
"      <sup>",
"       7",
"      </sup>",
"      per kg, regardless of HLA-disparity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 102 children and adults who underwent UCBT for malignant or non-malignant diseases noted that patients receiving a CD34+ cell dose &lt;1.7 x 10",
"      <sup>",
"       5",
"      </sup>",
"      per kg body weight had a slower neutrophil recovery at a median of 34 days (range, 17 to 54 days), inferior likelihood of engraftment, and a higher incidence of TRM [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another analysis compared outcomes of",
"      <sup>",
"      </sup>",
"      503 children with acute leukemia given an unrelated mismatched",
"      <sup>",
"      </sup>",
"      UCBT with 282 unrelated BM transplant recipients (116 HLA allele",
"      <sup>",
"      </sup>",
"      matched 8 out of 8 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/22\">",
"       22",
"      </a>",
"      ]). They observed higher TRM",
"      <sup>",
"      </sup>",
"      in children receiving a low UCB cell dose (TNC &lt;3 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        7",
"       </sup>",
"       /kg)",
"       <sup>",
"       </sup>",
"      </span>",
"      and one HLA disparate UCB graft; high TRM was also seen in children given a two HLA disparate",
"      <sup>",
"      </sup>",
"      UCBT, independently of the cell dose infused.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When evaluating potential UCB units for selection, efforts should be made to choose the unit(s) with the greatest HLA-match that have an acceptable TNC count. In general, units should have &ge;3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    or &ge;2 x 10",
"    <sup>",
"     5",
"    </sup>",
"    CD34+",
"    <span class=\"nowrap\">",
"     cells/kg.",
"    </span>",
"    In patients without malignant disease, the risk of rejection is higher and a cutoff of &ge;3.5 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    has been suggested based upon analyses in children demonstrating survival of &lt;10 percent if lower TNC doses were administered in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604507\">",
"    <span class=\"h3\">",
"     Combined cord blood units",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that single UCB samples frequently do not contain sufficient hematopoietic progenitor cells to allow for the reconstitution of the bone marrow of a large child or adult (eg, &gt;70 kg), studies have investigated infusing two cord blood units (ie, double unit UCB transplant) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. Patients receiving combined cord blood units have a more rapid time to neutrophil and platelet recovery. Double unit UCB transplantation (UCBT) is an acceptable alternative source of hematopoietic stem cells for persons without a single UCB unit of adequate cell dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When two UCB units are infused, there may be a transient chimerism with hematopoietic cells from both grafts followed by the sustained dominance of one unit by day 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/32\">",
"     32",
"    </a>",
"    ]. A prolonged state of mixed chimerism is more common in patients receiving a less intensive preparative regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/38\">",
"     38",
"    </a>",
"    ]. The dominant graft cannot be predicted based upon the number of nucleated cells, dose of CD34+ cells, CD3+ cells, cell viability studies, degree of HLA-match, high resolution HLA-matching, ABO group, sex of donor, or order and route of infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single center retrospective study of 177 patients undergoing single (47 percent) or double UCBT reported that recipients of double UCBT had similar rates of sustained engraftment (86 versus 90 percent), time to neutrophil recovery (25 versus 22 days), and treatment-related mortality at one year (29 versus 26 percent), but a higher incidence of acute graft-versus-host disease (25 versus 12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing trials are investigating whether double unit transplant is better than single unit transplant in children. The best markers of unit potency are CD34 cell and colony forming units (CFUs) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Costs and GVHD may be increased with double cord blood transplant.",
"   </p>",
"   <p>",
"    A single-institution case series of 84 consecutive recipients of double-unit UCBT for the treatment of high-risk hematologic malignancy investigated factors associated with the preferential engraftment of a single cord blood unit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained donor engraftment was attained in 93 and 96 percent of patients undergoing myeloablative and nonmyeloablative preparative regimens, respectively. Patients undergoing nonmyeloablative UCBT had an initial autologous recovery of neutrophils followed by donor engraftment resulting in a shorter median time to neutrophil recovery (9.5 versus 23 days). By day 21, donor hematopoiesis was derived from a single unit in 87 and 64 percent of patients undergoing myeloablative and nonmyeloablative UCBT, respectively.",
"     </li>",
"     <li>",
"      Factors predicting unit dominance included a higher infused total nucleated cell (TNC) count, greater percentage of viable CD34+ cells post-thaw, and colony-forming unit assay, in descending order of importance.",
"     </li>",
"     <li>",
"      The total infused graft TNC, CD34+ cell, colony forming units, and CD3+ cell dose was associated with a higher likelihood of sustained donor engraftment and faster neutrophil recovery after myeloablative conditioning.",
"     </li>",
"     <li>",
"      Unit-recipient HLA match does not influence the likelihood of sustained donor engraftment, time to neutrophil recovery, or unit dominance. Unit-unit HLA match does not affect sustained donor engraftment or speed of neutrophil recovery.",
"     </li>",
"     <li>",
"      High level of unit-unit HLA match is associated with an increased likelihood of engraftment of both units.",
"     </li>",
"     <li>",
"      Sustained engraftment was seen in cases with extensive donor-recipient HLA disparity as little as",
"      <span class=\"nowrap\">",
"       2/10",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       3/10",
"      </span>",
"      HLA match. Increasing HLA match from",
"      <span class=\"nowrap\">",
"       4/6",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       6/6",
"      </span>",
"      or from",
"      <span class=\"nowrap\">",
"       6/6",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      has not been associated with better engraftment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/32,43\">",
"       32,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4260926\">",
"    <span class=\"h3\">",
"     Improving cell dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of UCB for transplantation is limited by the numbers of hematopoietic progenitors in the graft. Low cell dose results in delayed engraftment and a high rate of graft failure. As described above, improvements in UCB engraftment have been observed following the infusion of two cord blood units (ie, double unit UCB transplant). Other modalities for improving cell dose have been studied, such as ex vivo expansion of UCB units and the infusion of an UCB unit with a limited number of mobilized peripheral blood progenitor cells from an HLA unrestricted third party donor or haploidentical donor (ie, dual transplants). Initial reports of these techniques are described below. &nbsp;",
"   </p>",
"   <p>",
"    Infusion of mobilized peripheral blood progenitor cells (PBPCs) from a nonmaternal HLA haploidentical relative may allow for the durable engraftment of single UCB units in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In one study, 45 patients received a reduced intensity conditioning regimen followed by infusion of a matched UCB unit and HLA haploidentical PBPCs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/45\">",
"     45",
"    </a>",
"    ]. Most patients demonstrated early transient haploidentical engraftment followed by permanent UCB engraftment with or without evidence of minor host- or haploidentical-derived hematopoiesis. The median times to neutrophil and platelet engraftment were 11 and 19 days, respectively. The cumulative incidences of acute and chronic GVHD were 25 and 6 percent at one year.",
"   </p>",
"   <p>",
"    In another study, 24 adults with hematologic cancers were treated with myeloablative conditioning followed by the infusion of one unmanipulated UCB unit and one UCB unit that had undergone ex vivo expansion in culture supported by mesenchymal stromal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/46\">",
"     46",
"    </a>",
"    ]. Ex vivo culture increased graft total nucleated cell (TNC) and CD34+ cell counts by a median factor of 12.2 and 30.1, respectively. As a result, the median infused TNC and CD34+ cell doses were 8.34 x 10",
"    <sup>",
"     7",
"    </sup>",
"    and 1.81 x 10",
"    <sup>",
"     6",
"    </sup>",
"    cells per kg, respectively. One patient did not engraft and died of fungal sepsis on day 30. When compared with 80 matched historical controls that received two unmanipulated UCB grafts, patients who received an expanded UCB graft had shorter median times to neutrophil engraftment (15 versus 24 days) and platelet engraftment (42 versus 49 days). The cumulative incidence of acute GVHD was 42 percent (13 percent grade",
"    <span class=\"nowrap\">",
"     III/IV).",
"    </span>",
"    Chronic GVHD was seen in 45 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604514\">",
"    <span class=\"h3\">",
"     Cell dose for non-myeloablative UCBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the optimal cell dose for unrelated UCB transplant (UCBT) in adults is yet to be determined, but, in general, a minimum of 3 x 10",
"    <sup>",
"     7",
"    </sup>",
"    nucleated",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    would be a reasonable target. Less is known about the minimal cell dose for durable engraftment in the context of UCBT following a non-myeloablative conditioning regimen. With non-myeloablative conditioning and unrelated, mismatched donors, the concern over rejection of UCB is increased. The underlying diseases for which the transplant was performed also affected the risk of engraftment failure, with a trend toward greater risk of graft failure in recipients with prior history of a bone marrow failure syndrome, chronic myeloid leukemia, hemoglobinopathies, or storage diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=see_link&amp;anchor=H1254202#H1254202\">",
"     \"Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens\", section on 'Non-myeloablative preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential strategies to overcome the risk of graft rejection include the use of graft with higher cell dose, graft that has been ex-vivo expanded, combinations of multiple cord blood units, and the use of modified protocol that conveys a higher degree of pre-transplant immunosuppression to overcome transfusion-induced-sensitization in patients with bone marrow failure syndromes and hemoglobinopathies. Optimizing postgrafting immunosuppression and modifying the duration of GVHD prophylaxis might be another promising approach in the context of allogeneic transplant following non-myeloablative preparative regimen.",
"   </p>",
"   <p>",
"    A retrospective single-center analysis of 536 patients from a matched-related donor (204 patients), HLA allele-matched unrelated donor (152 patients), one antigen-mismatched unrelated adult donor (52 patients), or 4 to 6 of 6 HLA-matched double UCB (128 patients) graft after myeloablative conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/47\">",
"     47",
"    </a>",
"    ]. Leukemia-free survival at five years was similar for each donor type (ranging from 33 to 51 percent). When compared with other donor sources, double UCB resulted in a lower risk of relapse (15 versus 35 to 43 percent), yet higher rates of nonrelapse mortality (34 versus 14 to 24 percent). Leukemia-free survival after double UCB transplantation is comparable with that observed after matched related donor and matched unrelated donor transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61604521\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may influence UCB unit selection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bank of origin &mdash; UCB banks that are accredited by NetCord-FACT are preferred. UCB quality, reliability of unit information, turnaround time, fees, and communication may vary from bank to bank [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RBC content &mdash; UCB units are typically processed prior to freezing to remove red blood cells (RBC depleted units), plasma, or both. UCB samples that have not had their red cells removed require washing prior to administration to remove red cell debris and free hemoglobin that may cause significant infusion reactions. In addition, unprocessed UCB units will typically contain more dimethyl sulphoxide (DMSO).",
"     </li>",
"     <li>",
"      Infectious disease monitoring &mdash; Donor mothers should be screened for hepatitis B, HIV, syphilis, HTLV-1, HTLV-2, and cytomegalovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/17\">",
"       17",
"      </a>",
"      ]. UCB units should be analyzed for sterility with bacterial and fungal cultures. In addition, more recently collected units are tested for West Nile virus and Chagas disease.",
"     </li>",
"     <li>",
"      Hematologic disease screening &mdash; UCB should be screened for hematologic diseases with a blood film and hemoglobinopathy screening prior to storage. Units with normal hemoglobin analysis and those with AF are acceptable. If other UCB units are not available for an individual, the use of UCB units that are heterozygous for either sickle cell trait or thalassemia (but not both) may be considered [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15865/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age of stored unit &mdash; There are no published data regarding the effect of storage duration on outcomes after UCB transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61605643\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical cord blood (UCB), the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an established alternative source of hematopoietic stem cells in allogeneic hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H61604472\">",
"       'Demand for cord blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unrelated UCB offers many practical advantages over unrelated donor bone marrow or mobilized peripheral blood progenitor cells as a source of hematopoietic stem cells including an expanded donor pool, ease of procurement and lack of donor attrition, and decreased graft-versus-host disease. (See",
"      <a class=\"local\" href=\"#H61604479\">",
"       'Advantages and limitations of cord blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limitations to UCB include an increased risk of graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). (See",
"      <a class=\"local\" href=\"#H61604479\">",
"       'Advantages and limitations of cord blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main criteria for selecting UCB unit(s) for transplantation are the human leukocyte antigen (HLA) haplotype and the cryopreserved total nucleated cell dose per kilogram recipient body weight. Outside the setting of a clinical trial, an acceptable approach is to choose UCB units with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The closest HLA match &mdash;",
"      <span class=\"nowrap\">",
"       &ge;4/6",
"      </span>",
"      HLA match (HLA-A, -B, -DRB1) or",
"      <span class=\"nowrap\">",
"       &ge;4/8",
"      </span>",
"      match (HLA-A, -B, -C, -DRB1) (see",
"      <a class=\"local\" href=\"#H61604493\">",
"       'HLA type'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Adequate cell dose &mdash; &ge;3 x 10",
"      <sup>",
"       7",
"      </sup>",
"      nucleated",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      or &ge;2 x 10",
"      <sup>",
"       5",
"      </sup>",
"      CD34+",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H61604500\">",
"       'Cell dose'",
"      </a>",
"      above)",
"      <br/>",
"      <br/>",
"      If there",
"      <sup>",
"      </sup>",
"      is no single unit with",
"      <sup>",
"      </sup>",
"      these characteristics then two units",
"      <sup>",
"      </sup>",
"      with a combined total",
"      <sup>",
"      </sup>",
"      dose of &ge;3 x 10",
"      <sup>",
"       7",
"      </sup>",
"      nucleated",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      and, if possible, not",
"      <sup>",
"      </sup>",
"      more than one HLA difference",
"      <sup>",
"      </sup>",
"      between the two units and the patient may be acceptable. In patients without malignant disease, the cell doses should be higher or the HLA incompatibility lower. (See",
"      <a class=\"local\" href=\"#H61604507\">",
"       'Combined cord blood units'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other factors that may influence UCB unit selection include the bank of origin, the red blood cell content, age of the stored unit, and screening for infectious and hematologic diseases. (See",
"      <a class=\"local\" href=\"#H61604521\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/1\">",
"      Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/2\">",
"      Navarrete C, Contreras M. Cord blood banking: a historical perspective. Br J Haematol 2009; 147:236.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.bmdw.org/ (Accessed on July 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/4\">",
"      Querol S, Rubinstein P, Marsh SG, et al. Cord blood banking: 'providing cord blood banking for a nation'. Br J Haematol 2009; 147:227.",
"     </a>",
"    </li>",
"    <li>",
"     Howe CW, Radde-Stepaniak T. Hematopoietic cell donor registries. In: Hematopoietic Cell Transplantation, 2nd ed, Thomas ED, Blume KG, Forman SJ (Eds), Blackwell Science, Malden 1999. p.503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/6\">",
"      Barker JN, Wagner JE. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/7\">",
"      Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/8\">",
"      Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/9\">",
"      Gluckman E, Rocha V, Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus Clin Biol 2001; 8:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/10\">",
"      Barker JN, Krepski TP, DeFor TE, et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002; 8:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/11\">",
"      Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/12\">",
"      Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/13\">",
"      Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/14\">",
"      Delaney C, Gutman JA, Appelbaum FR. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009; 147:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/15\">",
"      Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009; 147:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/16\">",
"      Daikeler T, Labopin M, Ruggeri A, et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/17\">",
"      Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/18\">",
"      Stotler C, Bolwell B, Sobecks R, et al. Are backup BM harvests worthwhile in unrelated donor allogeneic transplants? Bone Marrow Transplant 2010; 45:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/19\">",
"      Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/20\">",
"      Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/21\">",
"      Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol 2011; 12:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/22\">",
"      Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/23\">",
"      Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/24\">",
"      Stevens CE, Carrier C, Carpenter C, et al. HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood 2011; 118:3969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/25\">",
"      Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118:6691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/26\">",
"      Rocha V, Gluckman E, Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009; 147:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/27\">",
"      Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011; 117:3277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/28\">",
"      McCullough J, McKenna D, Kadidlo D, et al. Mislabeled units of umbilical cord blood detected by a quality assurance program at the transplantation center. Blood 2009; 114:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/29\">",
"      Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/30\">",
"      Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/31\">",
"      Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/32\">",
"      Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/33\">",
"      Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/34\">",
"      Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007; 13:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/35\">",
"      Chen YB, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia 2008; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/36\">",
"      Scaradavou A, Brunstein CG, Eapen M, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood 2013; 121:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/37\">",
"      Sideri A, Neokleous N, Brunet De La Grange P, et al. An overview of the progress on double umbilical cord blood transplantation. Haematologica 2011; 96:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/38\">",
"      Berglund S, Okas M, Gertow J, et al. Stable mixed donor-donor chimerism after double cord blood transplantation. Int J Hematol 2009; 90:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/39\">",
"      Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/40\">",
"      Migliaccio AR, Adamson JW, Stevens CE, et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000; 96:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/41\">",
"      Yoo KH, Lee SH, Kim HJ, et al. The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant 2007; 39:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/42\">",
"      Alonso JM 3rd, Regan DM, Johnson CE, et al. A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences. Cytotherapy 2001; 3:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/43\">",
"      Scaradavou A, Smith KM, Hawke R, et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 2010; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/44\">",
"      Fern&aacute;ndez MN. Improving the outcome of cord blood transplantation: use of mobilized HSC and other cells from third party donors. Br J Haematol 2009; 147:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/45\">",
"      Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 2011; 118:6438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/46\">",
"      de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/47\">",
"      Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116:4693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15865/abstract/48\">",
"      Rosenau EH, Sugrue MW, Haller M, et al. Characteristics of thawed autologous umbilical cord blood. Transfusion 2012; 52:2234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16563 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15865=[""].join("\n");
var outline_f15_31_15865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H61605643\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2564267\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61604465\">",
"      CORD BLOOD AS A RESOURCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61604472\">",
"      Demand for cord blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61604479\">",
"      Advantages and limitations of cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61604486\">",
"      CORD BLOOD UNIT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61604493\">",
"      HLA type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61604500\">",
"      Cell dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4260919\">",
"      - Importance of cell dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61604507\">",
"      - Combined cord blood units",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4260926\">",
"      - Improving cell dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61604514\">",
"      - Cell dose for non-myeloablative UCBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61604521\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61605643\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/14/39145?source=related_link\">",
"      Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15866="Preterm premature rupture of membranes";
var content_f15_31_15866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preterm premature rupture of membranes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Patrick Duff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/31/15866/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/31/15866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature rupture of membranes (PROM) refers to membrane rupture before the onset of uterine contractions; preterm PROM (PPROM) is the term used when the pregnancy is less than 37 completed weeks of gestation. PPROM occurs in 3 percent of pregnancies and is responsible for, or associated with, approximately one-third of preterm births.",
"   </p>",
"   <p>",
"    The management of PPROM is among the most controversial issues in perinatal medicine. Points of contention include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Expectant management versus intervention",
"     </li>",
"     <li>",
"      Use of tocolytics",
"     </li>",
"     <li>",
"      Duration of administration of antibiotic prophylaxis",
"     </li>",
"     <li>",
"      Timing of administration of antenatal corticosteroids",
"     </li>",
"     <li>",
"      Methods of testing for",
"      <span class=\"nowrap\">",
"       maternal/fetal",
"      </span>",
"      infection",
"     </li>",
"     <li>",
"      Timing of delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors, diagnosis, and management of PPROM at 24 to 37 weeks of gestation will be discussed here. Issues specifically relating to management of PROM prior to 24 weeks of gestation and at term are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link\">",
"     \"Midtrimester preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4407?source=see_link\">",
"     \"Management of premature rupture of the fetal membranes at term\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of PPROM is not completely understood. Multiple etiologies, mechanical and physiological, probably share a final common pathway leading to membrane rupture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43175?source=see_link&amp;anchor=H15#H15\">",
"     \"Fetal membranes: Anatomy and biochemistry\", section on 'Pathogenesis of rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for PPROM are similar to those for preterm labor (",
"    <a class=\"graphic graphic_table graphicRef68992 \" href=\"UTD.htm?27/48/28428\">",
"     table 1",
"    </a>",
"    ). A history of PPROM in a previous pregnancy, genital tract infection, antepartum bleeding, and cigarette smoking have a particularly strong association with PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a small randomized trial suggested vitamin C supplementation might lower the risk of PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/2\">",
"     2",
"    </a>",
"    ], a larger randomized trial in which both vitamin C and E were given refuted this finding and suggested the risk of PPROM may actually be increased with antioxidant supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous PPROM &mdash; Studies have consistently shown that a history of PPROM is a significant risk factor for recurrence. As an example, the Preterm Prediction Study, a large prospective study conducted by the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, observed that women with a history of PPROM had a 13.5 percent rate of PPROM in a subsequent pregnancy compared to 4.1 percent in women with no such history (RR 3.3, 95% CI 2.1-5.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/4\">",
"       4",
"      </a>",
"      ]. Women with a history of PPROM are at risk for recurrent PPROM or preterm birth without PPROM [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genital infection &mdash; Genital tract infection is the single most common identifiable risk factor for PPROM. Three lines of epidemiologic evidence strongly support this association: (1) women with PPROM are significantly more likely than women with intact membranes to have pathogenic microorganisms in the amniotic fluid, (2) women with PPROM have a significantly higher rate of histologic chorioamnionitis than those who deliver preterm without PPROM, and (3) the frequency of PPROM is significantly higher in women with certain lower genital tract infections (particularly bacterial vaginosis) than in uninfected women [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The association between bacterial colonization of the genital tract and PPROM is not surprising. Many of the microorganisms that colonize the lower genital tract have the capacity to produce phospholipases, which can stimulate the production of prostaglandins and thereby lead to the onset of uterine contractions. In addition, the host's immune response to bacterial invasion of the endocervix",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal membranes leads to the production of multiple inflammatory mediators that can cause localized weakening of the fetal membranes and result in PPROM [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/7\">",
"       7",
"      </a>",
"      ]. Genetic regulation of the host's immune and inflammatory response appears to play a role in susceptibility and response to infections associated with PPROM. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"       \"Risk factors for preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antepartum bleeding &mdash; Antepartum bleeding in the first trimester is associated with a small but statistically significant increase in the risk of PPROM [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/8\">",
"       8",
"      </a>",
"      ]. Antepartum bleeding in more than one trimester increases the risk of PPROM three to seven-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/1,9,10\">",
"       1,9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"       \"Risk factors for preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cigarette smoking &mdash; The risk of PPROM among smokers is increased two to four-fold compared to nonsmokers. The risk persists even after adjustment for other known risk factors for PPROM, including infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"       \"Smoking and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of women with PPROM develop potentially serious infections, such as intraamniotic infection (chorioamnionitis and funisitis), endometritis, or septicemia. Endometritis is more common after cesarean than vaginal delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fetus and neonate are at greater risk of PPROM-related morbidity and mortality than the mother. The majority of pregnancies with PPROM deliver preterm and within one week of membrane rupture. Preterm infants are especially vulnerable to a variety of problems, such as hyaline membrane disease, intraventricular hemorrhage, periventricular leukomalacia and other neurologic sequelae, infection (eg, sepsis, pneumonia, meningitis), and necrotizing enterocolitis. The rates of these morbidities vary with gestational age and are higher in the setting of chorioamnionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PPROM is also associated with increased risks of abruptio placentae and prolapse of the umbilical cord. Placental abruption occurs in 2 to 5 percent of pregnancies complicated by PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The risk is increased seven- to nine-fold in PPROM pregnancies in which intrauterine infection or oligohydramnios is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Placental abruption may be the precipitating event for or a consequence of PPROM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link&amp;anchor=H3#H3\">",
"     \"Placental abruption: Clinical features and diagnosis\", section on 'Pathogenesis and pathophysiology'",
"    </a>",
"    .) Fetal malpresentation is common, given the preterm gestational age and the frequent occurrence of reduced amniotic fluid volume. The risk of cord prolapse is especially high (11 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/16\">",
"     16",
"    </a>",
"    ]) in the setting of both nonvertex fetal presentation and PPROM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=see_link\">",
"     \"Umbilical cord prolapse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early, severe, prolonged oligohydramnios can be associated with pulmonary hypoplasia, facial deformation, and orthopedic abnormalities. Such complications are most likely when membrane rupture occurs at less than 23 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link&amp;anchor=H15#H15\">",
"     \"Midtrimester preterm premature rupture of membranes\", section on 'Pediatric outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PPROM is clinical, and is generally based on a combination of a characteristic history and visualization of amniotic fluid on physical examination. Laboratory tests may be used to confirm the clinical diagnosis when there is uncertainty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical presentation of PPROM is a sudden \"gush\" of clear or pale yellow fluid from the vagina. However, many women describe intermittent or constant leaking of small amounts of fluid or just a sensation of wetness within the vagina or on the perineum. A clinical history suggestive of PPROM should be confirmed by visual inspection or laboratory tests to exclude other causes of",
"    <span class=\"nowrap\">",
"     vaginal/perineal",
"    </span>",
"    wetness, such as urinary incontinence, vaginal discharge, and perspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best method of confirming the diagnosis of PPROM is direct observation of amniotic fluid coming out of the cervical canal or pooling in the vaginal fornix. If amniotic fluid is not immediately visible, the woman can be asked to push on her fundus, Valsalva, or cough to provoke leakage of amniotic fluid from the cervical os. Digital examination should be avoided because it may decrease the latency period (ie, time from rupture of membranes to delivery) and increase the risk of intrauterine infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Nitrazine and fern tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;If PROM is not obvious after visual inspection, the diagnosis can be confirmed by testing the pH of the vaginal fluid, which is easily accomplished with nitrazine paper. Amniotic fluid usually has a pH range of 7.0 to 7.3 compared to the normally acidic vaginal pH of 3.8 to 4.2 (",
"    <a class=\"graphic graphic_picture graphicRef56755 \" href=\"UTD.htm?0/53/848\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-negative and false-positive nitrazine test results occur in up to 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. False negative tests results can occur when leaking is intermittent or the amniotic fluid is diluted by other vaginal fluids. False positive results can be due to the presence of alkaline fluids in the vagina, such as blood, seminal fluid, or soap. In addition, the pH of urine can be elevated to near 8.0 if infected with Proteus species.",
"   </p>",
"   <p>",
"    A second confirmatory test is the presence of arborization (ferning). Fluid from the posterior vaginal fornix is swabbed onto a glass slide and allowed to dry for at least 10 minutes. Amniotic fluid produces a delicate ferning pattern, in contrast to the thick and wide arborization pattern of dried cervical mucus (",
"    <a class=\"graphic graphic_picture graphicRef78666 \" href=\"UTD.htm?22/53/23386\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61431 \" href=\"UTD.htm?27/56/28553\">",
"     picture 3",
"    </a>",
"    ). Well-estrogenized cervical mucus or a fingerprint on the microscope slide may cause a false-positive fern test; false negatives can be due to inadequate amniotic fluid on the swab or heavy contamination with vaginal discharge or blood.",
"   </p>",
"   <p>",
"    In the United Kingdom, an absorbent pad (AmnioSense) that changes color at pH &gt; 5.2 is used as a panty liner and marketed to pregnant women. In a study of 157 pregnant women, the sensitivity and specificity of this device for diagnosis of membrane rupture were 98 and 65 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination may be of value in the diagnosis of PPROM. Fifty to 70 percent of women with PPROM have low amniotic fluid volume on initial sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/24\">",
"     24",
"    </a>",
"    ]. A mild reduction of amniotic fluid volume may have many etiologies. On the other hand, the finding of anhydramnios or severe oligohydramnios, combined with a characteristic history, is highly suggestive of rupture of membranes, although renal agenesis, obstructive uropathy, or severe utero-placental insufficiency also can cause marked reductions in amniotic fluid volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=see_link\">",
"     \"Assessment of amniotic fluid volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Instillation of indigo carmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In equivocal cases, instillation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    into the amniotic cavity can be considered and usually leads to a definitive diagnosis. Under ultrasound guidance, 1 mL of indigo carmine in 9 mL of sterile saline is injected transabdominally into the amniotic fluid and a tampon is placed in the vagina. One-half hour later, the tampon is removed and examined for blue staining, which indicates leakage of amniotic fluid. This test is rarely indicated, given the availability of the non-invasive AmniSure test and the risks of amniocentesis (eg, rupture of membranes, fetal injury).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Placental alpha microglobulin-1 protein assay (AmniSure)",
"    </span>",
"    &nbsp;&mdash;&nbsp;AmniSure&reg; is a rapid slide test that uses immunochromatographic methods to detect trace amounts of placental alpha microglobulin-1 protein in vaginal fluid. An advantage of this test is that it is not affected by semen or trace amounts of blood.",
"   </p>",
"   <p>",
"    The test is done by the provider at the point of care using a commercially available kit. A sterile swab is inserted into the vagina for one minute, then placed into a vial containing a solvent for one minute, and then an AmniSure test strip is dipped into the vial. The test result is revealed by the presence of one or two lines within the next 5 to 10 minutes (one visible line means a negative result for amniotic fluid, two visible lines is a positive result, no visible lines is an invalid result). The test costs 35 to 45 US dollars per use. Two large studies have assessed its efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 203 gravidas suspected of ruptured membranes, the sensitivity and specificity of the AmniSure device were 98.9 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/25\">",
"       25",
"      </a>",
"      ]. Test performance was calculated by comparing AmniSure results against clinical history, nitrazine and fern results, presence of pooling, sonographic evidence of oligohydramnios, and findings from repeated examinations.",
"     </li>",
"     <li>",
"      Another study of 184 gravidas suspected of ruptured membranes reported the sensitivity and specificity of the AmniSure device were 98.7 and 87.5 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/26\">",
"       26",
"      </a>",
"      ]. Test performance was calculated similar to the method described above. The cause of false positive results in three patients was unknown; the possibility of a small leak that sealed over could not be excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the relatively high cost of this test, we suggest limiting its use to cases where the diagnosis remains uncertain after physical and ultrasound examination and Nitrazine and fern tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2872779931\">",
"    <span class=\"h3\">",
"     Insulin-like growth factor binding protein 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of insulin-like growth factor binding protein 1 (IGFBP-1) also may be of value in confirming the diagnosis of PPROM in problematic cases. This protein is secreted by decidual and placental cells and has a very high concentration in amniotic fluid compared to other body fluids. An easy-to-use, immunochromatographic dipstick method (eg, actim&trade;Prom) is available in some countries for use at the bedside to detect IGFBP-1 in vaginal secretions; a positive test is denoted by the presence of two blue lines on the dipstick. The test is not affected by the presence of infected vaginal secretions, urine, semen, or small amounts of blood.",
"   </p>",
"   <p>",
"    The test is most accurate when applied as soon as possible after rupture of membranes. Sensitivity in detecting ruptured membranes ranges from 95 to 100 percent, specificity ranges from 93 to 98 percent, and positive predictive value approaches 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. The test is particularly helpful in identifying those women likely to deliver within seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H879788\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pregnancies complicated by PPROM is based upon consideration of several factors, which are assessed upon presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gestational age",
"     </li>",
"     <li>",
"      Availability of neonatal intensive care",
"     </li>",
"     <li>",
"      Presence or absence of",
"      <span class=\"nowrap\">",
"       maternal/fetal",
"      </span>",
"      infection",
"     </li>",
"     <li>",
"      Presence or absence of labor",
"     </li>",
"     <li>",
"      Fetal presentation (breech and transverse lies are unstable and may increase the risk for cord prolapse)",
"     </li>",
"     <li>",
"      Fetal heart rate (FHR) tracing pattern",
"     </li>",
"     <li>",
"      Likelihood of fetal lung maturity",
"     </li>",
"     <li>",
"      Cervical status (by visual, not digital, inspection unless induction is planned or the woman is in labor)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of PPROM from 26 to &ge;37 weeks will be discussed here. Issues specifically relating to management of midtrimester PPROM and PROM at term are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link\">",
"     \"Midtrimester preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4407?source=see_link\">",
"     \"Management of premature rupture of the fetal membranes at term\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our simplified algorithm for management of women with PPROM at 26 to 36 weeks is shown in the link (",
"    <a class=\"graphic graphic_algorithm graphicRef64412 \" href=\"UTD.htm?33/11/33982\">",
"     algorithm 1",
"    </a>",
"    ). A detailed analysis of the nuances of management is beyond the scope of this topic review; however, several aspects of management will be discussed.",
"   </p>",
"   <p>",
"    Expeditious delivery of women with PPROM is indicated if intrauterine infection, abruptio placentae, repetitive FHR decelerations, or a high risk of cord prolapse is present or suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/31\">",
"     31",
"    </a>",
"    ]. In each of these conditions, fetal well-being can deteriorate with expectant management, and there are no therapeutic interventions available other than delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=see_link\">",
"     \"Umbilical cord prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with a practice bulletin by the American College of Obstetricians and Gynecologists (ACOG) that pregnancies &ge;34 weeks of gestation with documented fetal lung maturity achieve slightly better maternal and neonatal outcomes with delivery than with expectant management, as long as expert neonatal care is available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Timing of delivery for expectantly managed pregnancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a 2012 meta-analysis of randomized trials of induction of labor versus expectant management of women with PPROM between 34 and 37 weeks, induction did not result in statistically significant benefits or harms compared with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal",
"      <span class=\"nowrap\">",
"       infection/sepsis",
"      </span>",
"      (RR 1.02, 95% CI 0.63-1.65;",
"      <span class=\"nowrap\">",
"       34/721",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       31/707)",
"      </span>",
"     </li>",
"     <li>",
"      Neonatal sepsis confirmed by blood culture (RR 0.88, 95% CI 0.42-1.84;",
"      <span class=\"nowrap\">",
"       14/563",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       14/537)",
"      </span>",
"     </li>",
"     <li>",
"      Respiratory distress syndrome (RR 1.04, 95% CI 0.81-1.33;",
"      <span class=\"nowrap\">",
"       100/721",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       90/709)",
"      </span>",
"     </li>",
"     <li>",
"      Cesarean delivery (RR 1.12, 95% CI 0.88-1.42;",
"      <span class=\"nowrap\">",
"       121/718",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       104/699)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the largest and most recent trial included in the meta-analysis, the rates of neonatal sepsis and of clinical chorioamnionitis were lower with induction of labor than with expectant management, but like the overall meta-analysis results, the differences did not achieve statistically significance (neonatal sepsis:",
"    <span class=\"nowrap\">",
"     7/268",
"    </span>",
"    [2.6 percent] versus",
"    <span class=\"nowrap\">",
"     11/270",
"    </span>",
"    [4.1 percent], RR 0.64, 95% CI 0.25-1.6; clinical chorioamnionitis:",
"    <span class=\"nowrap\">",
"     6/266",
"    </span>",
"    [2.3 percent] versus",
"    <span class=\"nowrap\">",
"     15/266",
"    </span>",
"    [5.6 percent], RR 0.40, 95% CI 0.16-1.02), possibly because the trial was underpowered.",
"   </p>",
"   <p>",
"    Limitations of this meta-analysis preclude its generalizability. For example, fetal lung maturity was not determined in these trials and thus was not a factor in selecting patients who may or may not benefit from prolongation of pregnancy. We advocate assessment of fetal lung maturity as a factor for deciding the optimum time for delivery. Also, the effects of administration of prophylactic antibiotics could not be assessed as there was no standard practice and patient-level data were not analyzed; we advocate use of antibiotics to reduce the risk of",
"    <span class=\"nowrap\">",
"     maternal/fetal/neonatal",
"    </span>",
"    infection during expectant management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Meconium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of term and preterm PROM patients have generally reported that those with meconium-stained amniotic fluid have higher rates of both overt and subclinical chorioamnionitis and positive amniotic fluid cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Meconium release predisposes to infection by enhancing the growth of bacteria and lowering phagocytic capacity of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/36\">",
"     36",
"    </a>",
"    ]. However, it is also possible that in some cases meconium-like staining is actually pigment associated with decidual hemorrhage (abruption).",
"   </p>",
"   <p>",
"    Patients with PPROM and meconium-stained amniotic fluid should be evaluated for signs of chorioamnionitis. In the absence of these signs, meconium alone is not an indication for intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antenatal corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A course of corticosteroids should be given to pregnancies less than 32 weeks of gestation. Data supporting this recommendation were provided by two systematic reviews of randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] that showed neonatal death, RDS, IVH, NEC, and duration of neonatal respiratory support were significantly reduced by antenatal glucocorticoid treatment, without an increase in either maternal or neonatal infection. Mean risk reduction for these adverse events ranged from 30 to 60 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H27#H27\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antenatal corticosteroids after 32 weeks in women with PPROM is somewhat controversial, as treatment at this gestational age has not consistently resulted in benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/39\">",
"     39",
"    </a>",
"    ]. However, we generally administer a course of antenatal corticosteroids in such cases when there is documented fetal pulmonary immaturity and no evidence of chorioamnionitis. Studies that did not find a significant benefit of antenatal glucocorticoid therapy after 32 weeks in PPROM did not stratify women according to results of fetal lung maturity tests (mature versus immature); thus the value of steroid administration in this subgroup has not been adequately investigated. Other clinicians avoid antenatal glucocorticoid administration after 32 weeks of gestation in PPROM because of concerns about an increased risk of chorioamnionitis and the absence of proven benefit in this setting. This approach is reviewed separately.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H27#H27\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for antibiotic prophylaxis is that infection appears to be both a cause and consequence of PPROM and is related to preterm delivery. The goal of antibiotic therapy is to reduce the frequency of maternal and fetal infection and delay the onset of preterm labor (ie, prolong latency). The importance of reducing infection is underscored by studies suggesting a relationship between chorioamnionitis, duration of membrane rupture, and development of cerebral palsy or neurodevelopmental impairment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A Cochrane review of 22 placebo-controlled randomized trials involving 6800 women evaluated the use of antibiotics following PPROM before 37 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/40\">",
"     40",
"    </a>",
"    ]. Compared to",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment, antibiotic use was associated with significant reductions in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chorioamnionitis (RR 0.66, 95% CI 0.46-0.96)",
"     </li>",
"     <li>",
"      Babies born within 48 hours (RR 0.71, 95% CI 0.58-0.87) and 7 days (RR 0.79, 95% CI 0.71-0.89) of randomization",
"     </li>",
"     <li>",
"      Neonatal infection (RR 0.67, 95% CI 0.52-0.85),",
"     </li>",
"     <li>",
"      Use of surfactant (RR 0.83, 95% CI 0.72-0.96),",
"     </li>",
"     <li>",
"      Neonatal oxygen therapy (RR 0.88, 95% CI 0.81-0.96), and",
"     </li>",
"     <li>",
"      Abnormal cerebral ultrasound scan prior to hospital discharge (RR 0.81, 95% CI 0.68-0.98)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data were insufficient to determine whether any antibiotic regimen (drug, dose, duration) was better than another, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    was associated with an increased risk of neonatal necrotizing enterocolitis (RR 4.72, 95% CI 1.57-14.23). The validity of this association requires further investigation in large trials, given the wide confidence interval.",
"   </p>",
"   <p>",
"    A subsequent meta-analysis was limited to PPROM before 34 weeks of gestation, and reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A regimen with reasonable activity against the major pelvic pathogens should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/42\">",
"     42",
"    </a>",
"    ]. We recommend administering a seven-day course of antibiotic prophylaxis to all women with PPROM who are being managed expectantly. The preference is to give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    2 g intravenously every six hours for 48 hours, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg orally three times daily or 875 mg orally twice daily) for an additional five days. In addition, we recommend giving one dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (one gram orally) upon admission. Ampicillin specifically targets group B streptococcus, many aerobic gram-negative bacilli, and some anaerobes. Azithromycin specifically targets genital mycoplasmas, which can be important causes of chorioamnionitis in this setting, and also provides coverage of",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/43\">",
"     43",
"    </a>",
"    ], which is an important cause of neonatal conjunctivitis and pneumonitis.",
"   </p>",
"   <p>",
"    This regimen is similar to that shown to be effective in the National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network trial on antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/44\">",
"     44",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is given in lieu of a multiple day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (250, 333, or 500 mg three or four times per day), which has been used in several trials. The powder formulation of azithromycin is less expensive than the tablets, but may not be as well tolerated.",
"   </p>",
"   <p>",
"    A basic science investigation illustrates the importance of genital mycoplasmas in the pathogenesis of preterm labor and helps to explain why drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be valuable both in prolonging the latent period and reducing the frequency of infection and injury in the baby [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/45\">",
"     45",
"    </a>",
"    ]. In this study, 16 chronically instrumented rhesus monkeys underwent intraamniotic inoculation with&nbsp;Ureaplasma parvum.&nbsp;Uterine contractions began soon after inoculation, at which time six monkeys received no treatment, five received intravenous azithromycin for 10 days, and five received azithromycin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    for 10 days. Azithromycin significantly prolonged gestation by approximately seven days, significantly decreased the Ureaplasma colony count in the amniotic fluid, decreased the amniotic fluid concentration of proinflammatory mediators, and decreased the magnitude of histologic lung injury.&nbsp;Interestingly, dexamethasone and indomethacin did not further enhance the treatment effect of azithromycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24851190\">",
"    <span class=\"h4\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's history suggests a \"low risk\" for anaphylaxis (eg, isolated maculopapular rash without urticaria or pruritus), then we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    1 g intravenously every eight hours for 48 hours, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    500 mg orally four times daily for five days. These drugs provide coverage for both GBS and E Coli, the two major causes of neonatal infection. We also give a single oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    1 g. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient's history suggests a \"high risk\" for anaphylaxis (eg, anaphylaxis, angioedema, respiratory distress, urticaria, particularly if these symptoms occurred within 30 minutes of drug administration), we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    900 mg intravenously every eight hours for 48 hours plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    ideal body weight for two doses 24 hours apart, followed by oral clindamycin 300 mg every eight hours for five days. We also give a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    1 g.",
"   </p>",
"   <p>",
"    Prophylactic antibiotics may exert selective pressures for emergence of drug-resistant microorganisms. In addition, there is a theoretical concern that clinical infection may be more difficult to recognize or treat in patients who have received prophylactic antibiotics. These problems have not been observed in women with PPROM receiving antibiotic prophylaxis. Long-term adverse effects of antepartum prophylactic antibiotics for PPROM have not been observed in children followed to age 7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/46\">",
"     46",
"    </a>",
"    ]. This finding is in contrast to the observation from the same authors that in patients with spontaneous preterm labor and intact membranes, the rate of cerebral palsy was increased in children exposed to antibiotics in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment of overt infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who develop overt infection require therapy with therapeutic, rather than prophylactic, antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link&amp;anchor=H15#H15\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with PPROM who have an identifiable genital tract infection (eg, gonorrhea, chlamydia, bacterial vaginosis) that would not be eliminated by a prophylactic antibiotic regimen should receive antibiotics that specifically target the infection. (See individual topic reviews on each subject).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chemoprophylaxis for GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprophylaxis specifically for group B streptococcal (GBS) disease is indicated if GBS test results are positive or unknown and delivery is imminent, but is generally not given to women with recent (within five weeks) negative GBS test results.&nbsp;The intravenous portion of the regimen described above for PPROM prophylaxis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , 2 g intravenously every 6 hours for 48 hours) should provide adequate treatment for GBS-colonized women who are in labor at the time of admission or who go into labor within 48 hours of admission. As noted, this regimen of intravenous ampicillin, followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , is usually given for seven days.&nbsp;After completion of this regimen, antibiotics should be discontinued. If the patient&rsquo;s GBS culture is positive, specific prophylaxis for GBS colonization should be resumed when the patient subsequently goes into labor (",
"    <a class=\"graphic graphic_algorithm graphicRef60841 \" href=\"UTD.htm?40/5/41054\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testing to determine group B streptococcal (GBS) status and guidelines for chemoprophylaxis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H14#H14\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Approach to threatened preterm delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Women with HSV, HIV, or cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management of women with PPROM and genital herpes simplex virus (HSV) or HIV infection is controversial, and opinions about the best course of action diverge widely. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=see_link\">",
"     \"Genital herpes simplex virus infection and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Expectant management of women with PPROM and a cerclage is also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=see_link&amp;anchor=H15#H15\">",
"     \"Transvaginal cervical cerclage\", section on 'Management after PPROM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal indication for tocolysis in the setting of PPROM is to delay delivery for 48 hours to allow administration of corticosteroids. As a general rule, tocolytics should not be administered for more than 48 hours.&nbsp;They also should not be administered to patients who are in advanced labor (&gt;4 cm dilation) or who have any findings suggestive of subclinical or overt chorioamnionitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review evaluating pregnancy outcomes of women with PPROM who received or did not receive tocolysis found tocolytic therapy was associated with longer latency (mean difference 73 hours, 95% CI 20-126 hours), fewer births within 48 hours (RR 0.55, 95% CI 0.32-0.95), and a trend toward an increased risk of chorioamnionitis (RR 1.62, 95% CI 1.00-2.61), but no significant improvement in perinatal morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients in these studies did not consistently receive antenatal corticosteroids to reduce neonatal morbidity or antibiotics to prolong latency, which diverges with current standards of care and may explain the lack of improvement in clinically important outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;We hospitalize women with PPROM who have a viable fetus from the time of diagnosis until delivery, with few exceptions. Women are typically kept at modified bedrest and frequently assessed for evidence of infection or labor (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Maternal surveillance'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There have been only two randomized trials evaluating the safety of outpatient versus inpatient management of women with PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The smaller trial included only 21 women with PPROM as part of a larger study of antenatal day care versus in-hospital care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/51\">",
"     51",
"    </a>",
"    ]. The larger trial, which included 67 women with PPROM, randomly assigned one group to expectant management at home and the other to expectant management in the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/50\">",
"     50",
"    </a>",
"    ]. Both groups were managed similarly with bedrest, recording of temperature and pulse every six hours, daily charting of fetal movements, twice-weekly nonstress tests and complete blood count, and weekly ultrasound and visual examination of the cervix. There were no significant differences in maternal or neonatal outcomes between groups, but the home group had lower maternal costs. Only 18 percent of women met the strict safety criteria used for inclusion (",
"    <a class=\"graphic graphic_table graphicRef55156 \" href=\"UTD.htm?18/43/19131\">",
"     table 2",
"    </a>",
"    ) and three women managed at home delivered unexpectedly at outside hospitals. A small retrospective study also observed no significant differences in maternal or neonatal outcomes for hospital versus home care, but the small number of patients and lack of a standardized protocol are major limitations to interpreting the results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study to determine the safety of this approach is warranted before a routine policy of outpatient management can be recommended. In particular, the possibility and risks of severe maternal infection and of precipitous labor and delivery need to be addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/16,50\">",
"     16,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Tissue sealants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tissue sealants (eg, fibrin glue, gelatin sponge) have shown some success in stopping leakage in case reports. Neither the safety nor the efficacy of these sealants has been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link&amp;anchor=H24#H24\">",
"     \"Midtrimester preterm premature rupture of membranes\", section on 'Repair of leaks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6656918\">",
"    <span class=\"h2\">",
"     Amnioinfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis compared pregnancy outcome in patients who received antepartum transabdominal amnioinfusion versus those who received usual care for management of PPROM (four observational studies n = 147 pregnancies, three randomized trials n = 165 pregnancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/53\">",
"     53",
"    </a>",
"    ]. Amnioinfusion was associated with prolongation of the latent phase (mean difference between groups: observational studies 14.4 days, 95% CI 8.2&ndash;20.6 days; randomized trials 11.4 days, 95% CI -3.4&ndash;26.2), reduction of perinatal mortality&nbsp;(observational studies OR&nbsp;0.12, 95% CI 0.02&ndash;0.61; randomized trials OR 0.33, 95% CI 0.10-1.12), reduced frequency of pulmonary hypoplasia (observational studies OR 0.17 95% CI 0.04&ndash;0.78; randomized trials OR 0.30, 95% CI 0.05-1.7), and reduction in",
"    <span class=\"nowrap\">",
"     amnionitis/endometritis",
"    </span>",
"    (observational studies OR 0.94, 95% CI 0.33-2.68; randomized trials OR 0.28, 955 CI 0.11-0.69). Amnioinfusion was successful in maintaining adequate amniotic fluid in only about one-third of cases.",
"   </p>",
"   <p>",
"    Although the results of this systemic review and metaanalysis are promising, the available data are limited to a few small randomized trials of low quality and observational studies. To better understand whether amnioinfusion is beneficial in PPROM, more and better information is needed about the effects of specific amnioinfusion protocols, selection of patients (eg, gestational age at rupture of membranes), and other interventions (type, dose, and duration of antibiotics; use of corticosteroids) on perinatal outcome. Until better data are available to support a change in practice, we do not recommend antepartum amnioinfusion for patients with PPROM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Supplemental progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that administration of supplemental progesterone has any beneficial effects in women with PPROM. The potential value of progesterone supplementation in women with PPROM was evaluated in a trial that randomly assigned 69 women with PPROM at 20 to 30 weeks of gestation to receive weekly intramuscular injections of 17-hydroxyprogesterone (250 mg) or placebo from the time of diagnosis of membrane rupture to 34 weeks of gestation or delivery, whichever came first [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/54\">",
"     54",
"    </a>",
"    ]. Cervical dilation and gestational age at study entry were similar between groups.&nbsp;Treatment with progesterone had no significant effect on gestational age at delivery, interval between randomization and delivery, mode of delivery, mean birth weight, five-minute Apgar score, composite neonatal morbidity, or number of days of NICU care. The sample size was relatively small and may have been inadequate to detect clinically meaningful differences in outcome between the two groups. Until there is evidence of efficacy in PPROM, prophylactic administration of progesterone to women in this setting is not recommended.&nbsp;In women who are already taking supplemental progesterone because of a prior pregnancy with preterm delivery related to preterm labor or PPROM, we discontinue the medication upon diagnosis of PPROM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=see_link&amp;anchor=H14419387#H14419387\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Maternal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women with PPROM should be monitored for signs of infection; however, there is no consensus as to the best approach. At a minimum, routine clinical parameters (eg, maternal temperature, uterine tenderness and contractions, maternal and fetal heart rate) should be monitored. Amniocentesis to obtain amniotic fluid for Gram stain, culture, leukocyte esterase, and glucose concentration is more controversial. We do not routinely perform amniocentesis to screen for intraamniotic infection in asymptomatic women. An in-depth discussion of the diagnosis and management of intraamniotic infection can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"     \"Intraamniotic infection (chorioamnionitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Fetal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some type of fetal surveillance is generally employed (eg, kick counts, nonstress tests, biophysical profile [BPP]) to provide the clinician and patient some assurance of fetal well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/55\">",
"     55",
"    </a>",
"    ]; however, none of these tests has good sensitivity for predicting fetal infection, even when performed daily [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/56\">",
"     56",
"    </a>",
"    ]. The optimal type and frequency of testing has not been determined, and randomized trials to determine whether testing leads to an improvement in perinatal outcome have not been performed. The only randomized trial of fetal surveillance of women with PPROM randomly assigned these women to either a daily nonstress test or a biophysical profile [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/56\">",
"     56",
"    </a>",
"    ]. Neither test had good sensitivity for predicting maternal or fetal infection. Low amniotic fluid volume is associated with an increased risk of umbilical cord compression and shorter latency, but, as with other tests, the predictive value is low [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The weight of available evidence, although limited, suggests that Doppler surveillance is not useful for monitoring fetal status in PPROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/57-59\">",
"     57-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Timing of delivery for expectantly managed pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to timing delivery of women with PPROM is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef79817 \" href=\"UTD.htm?34/35/35387\">",
"     table 3",
"    </a>",
"    ). In general, prematurity is the greatest risk to the fetus with uncomplicated PPROM at less than 34 weeks of gestation. Therefore, we manage pregnancies at this gestational age expectantly in the absence of complications (eg, infection, abruption, cord prolapse, unstable fetal presentation, nonreassuring fetal assessment). As discussed above, we administer a course of antenatal corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    12 mg intramuscularly 24 hours apart for two doses or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    6 mg intramuscularly 12 hours apart for four doses), prophylactic antibiotics for seven days, and tocolytics for 48 hours, as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the pregnancy reaches 34 weeks, we attempt to aspirate amniotic fluid from the vaginal vault to test for fetal lung maturity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .) If testing shows a low risk of neonatal respiratory problems, we initiate delivery because we believe the risks of prematurity are small in this setting compared to the risk of developing maternal or fetal complications during expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/60\">",
"     60",
"    </a>",
"    ]. If we cannot aspirate fluid or testing suggests a high risk of neonatal respiratory problems, we continue to manage the patient expectantly until 36 weeks of gestation, at which time we proceed with delivery without resampling the fluid. Earlier delivery would be indicated if the patient developed clinical evidence of infection or abruption, went into labor, or fetal assessment was nonreassuring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Method of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of contraindications to labor and vaginal birth, most patients will deliver by spontaneous or induced vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/61\">",
"     61",
"    </a>",
"    ]. Cesarean delivery is performed for standard indications; otherwise labor is induced. We perform a digital cervical examination to determine whether cervical ripening has occurred. If the cervix is favorable,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is administered for induction according to standard protocols. Once cervical ripening has occurred, we prefer to use oxytocin over prostaglandins because oxytocin is more easily titrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Unfavorable cervix",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is also effective for inducing labor, and may be advantageous in women with an unfavorable cervix. A meta-analysis including 15 randomized trials of women with term PROM reported the rate of vaginal delivery in 12 and 24 hours was similar after administration of misoprostol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/62\">",
"     62",
"    </a>",
"    ]. Whether misoprostol was advantageous in the subgroup of women with an unfavorable cervix is unknown since this was not evaluated. The optimum dose and route of misoprostol administration have also not been determined. Prostaglandin E2 is a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/63\">",
"     63",
"    </a>",
"    ]. There is minimal information on the safety of mechanical methods of cervical ripening in PROM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/31/15866/abstract/64\">",
"     64",
"    </a>",
"    ]. We do not use these methods (eg, Foley bulb) due to concern that introducing a foreign body might increase the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link&amp;anchor=H92003909#H92003909\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\", section on 'Prostaglandin E1 (misoprostol)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159563783\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NEWBORN",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Maternal and neonatal risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=see_link\">",
"       \"Patient information: Preterm premature rupture of membranes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preterm premature rupture of membranes (PPROM) refers to rupture of fetal membranes prior to labor in pregnancies of less than 37 weeks. It occurs in 3 percent of pregnancies and is responsible for one-third of preterm births. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A history of PPROM, genital tract infection, antepartum bleeding, and cigarette smoking are risk factors for PPROM. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal and neonatal infection, preterm delivery, abruptio placenta, and cord prolapse are potential complications of PPROM. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical history suggestive of PPROM should be confirmed by visual inspection or diagnostic testing to exclude other causes of wetness, such as urinary incontinence, vaginal discharge, and perspiration. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of women with PPROM is based upon consideration of several factors, including gestational age, the availability of neonatal intensive care, the presence or absence of",
"      <span class=\"nowrap\">",
"       maternal/fetal",
"      </span>",
"      infection, the presence or absence of labor or abruptio placentae, the stability of the fetal presentation and fetal heart rate tracing pattern, the probability of fetal lung maturity, and cervical status (",
"      <a class=\"graphic graphic_algorithm graphicRef64412 \" href=\"UTD.htm?33/11/33982\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with PPROM in whom intrauterine infection, abruptio placentae, repetitive fetal heart rate decelerations, or a high risk of cord prolapse is present or suspected, expeditious delivery is indicated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For stable patients with PPROM &lt;34 weeks, we suggest expectant management (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In addition: (See",
"      <a class=\"local\" href=\"#H879788\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administering a course of antenatal corticosteroids to enhance fetal lung maturation in pregnancies less than 32 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest administering a course of glucocorticoid between 32 and 34 weeks of gestation when there is documented fetal pulmonary immaturity and no evidence of chorioamnionitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antenatal corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend prophylactic antibiotics (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Our preference is to give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      2 g intravenously every six hours for 48 hours, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg orally three times daily or 875 mg orally twice daily) for an additional five days. In addition, we give one dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      (one gram orally) at the time of admission and repeat the dose five days later. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest delivery at &ge;34 weeks of gestation upon documentation of fetal lung maturity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the absence of documented fetal lung maturity, we suggest delivery at 36 weeks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Timing of delivery for expectantly managed pregnancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/1\">",
"      Harger JH, Hsing AW, Tuomala RE, et al. Risk factors for preterm premature rupture of fetal membranes: a multicenter case-control study. Am J Obstet Gynecol 1990; 163:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/2\">",
"      Casanueva E, Ripoll C, Tolentino M, et al. Vitamin C supplementation to prevent premature rupture of the chorioamniotic membranes: a randomized trial. Am J Clin Nutr 2005; 81:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/3\">",
"      Spinnato JA 2nd, Freire S, Pinto e Silva JL, et al. Antioxidant supplementation and premature rupture of the membranes: a planned secondary analysis. Am J Obstet Gynecol 2008; 199:433.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/4\">",
"      Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/5\">",
"      Lee T, Carpenter MW, Heber WW, Silver HM. Preterm premature rupture of membranes: risks of recurrent complications in the next pregnancy among a population-based sample of gravid women. Am J Obstet Gynecol 2003; 188:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/6\">",
"      Ekwo EE, Gosselink CA, Moawad A. Unfavorable outcome in penultimate pregnancy and premature rupture of membranes in successive pregnancy. Obstet Gynecol 1992; 80:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/7\">",
"      Parry S, Strauss JF 3rd. Premature rupture of the fetal membranes. N Engl J Med 1998; 338:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/8\">",
"      Lykke JA, Dideriksen KL, Lidegaard O, Langhoff-Roos J. First-trimester vaginal bleeding and complications later in pregnancy. Obstet Gynecol 2010; 115:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/9\">",
"      Ekwo EE, Gosselink CA, Woolson R, Moawad A. Risks for premature rupture of amniotic membranes. Int J Epidemiol 1993; 22:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/10\">",
"      Berkowitz GS, Blackmore-Prince C, Lapinski RH, Savitz DA. Risk factors for preterm birth subtypes. Epidemiology 1998; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/11\">",
"      Soraisham AS, Singhal N, McMillan DD, et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol 2009; 200:372.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/12\">",
"      Williams MA, Lieberman E, Mittendorf R, et al. Risk factors for abruptio placentae. Am J Epidemiol 1991; 134:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/13\">",
"      Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ. Preterm premature rupture of the membranes: a risk factor for the development of abruptio placentae. Am J Obstet Gynecol 1987; 156:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/14\">",
"      Ananth CV, Oyelese Y, Srinivas N, et al. Preterm premature rupture of membranes, intrauterine infection, and oligohydramnios: risk factors for placental abruption. Obstet Gynecol 2004; 104:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/15\">",
"      Major CA, de Veciana M, Lewis DF, Morgan MA. Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications? Am J Obstet Gynecol 1995; 172:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/16\">",
"      Lewis DF, Robichaux AG, Jaekle RK, et al. Expectant management of preterm premature rupture of membranes and nonvertex presentation: what are the risks? Am J Obstet Gynecol 2007; 196:566.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/17\">",
"      Alexander JM, Mercer BM, Miodovnik M, et al. The impact of digital cervical examination on expectantly managed preterm rupture of membranes. Am J Obstet Gynecol 2000; 183:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/18\">",
"      Schutte MF, Treffers PE, Kloosterman GJ, Soepatmi S. Management of premature rupture of membranes: the risk of vaginal examination to the infant. Am J Obstet Gynecol 1983; 146:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/19\">",
"      Imseis HM, Trout WC, Gabbe SG. The microbiologic effect of digital cervical examination. Am J Obstet Gynecol 1999; 180:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/20\">",
"      Seeds AE, Hellegers AE. Acid-base determinations in human amniotic fluid throughout pregnancy. Am J Obstet Gynecol 1968; 101:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/21\">",
"      Abe, T. The detection of rupture of fetal membranes with the nitrazine indicator. Am J Obstet Gynecol 1940; 39:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/22\">",
"      Davidson KM. Detection of premature rupture of the membranes. Clin Obstet Gynecol 1991; 34:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/23\">",
"      Mulhair L, Carter J, Poston L, et al. Prospective cohort study investigating the reliability of the AmnioSense method for detection of spontaneous rupture of membranes. BJOG 2009; 116:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/24\">",
"      Mercer BM, Rabello YA, Thurnau GR, et al. The NICHD-MFMU antibiotic treatment of preterm PROM study: impact of initial amniotic fluid volume on pregnancy outcome. Am J Obstet Gynecol 2006; 194:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/25\">",
"      Cousins LM, Smok DP, Lovett SM, Poeltler DM. AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. Am J Perinatol 2005; 22:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/26\">",
"      Lee SE, Park JS, Norwitz ER, et al. Measurement of placental alpha-microglobulin-1 in cervicovaginal discharge to diagnose rupture of membranes. Obstet Gynecol 2007; 109:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/27\">",
"      Akercan F, Cirpan T, Kazandi M, et al. The value of the insulin-like growth factor binding protein-1 in the cervical-vaginal secretion detected by immunochromatographic dipstick test in the prediction of delivery in women with clinically unconfirmed preterm premature rupture of membranes. Eur J Obstet Gynecol Reprod Biol 2005; 121:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/28\">",
"      Darj E, Lyren&auml;s S. Insulin-like growth factor binding protein-1, a quick way to detect amniotic fluid. Acta Obstet Gynecol Scand 1998; 77:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/29\">",
"      Erdemoglu E, Mungan T. Significance of detecting insulin-like growth factor binding protein-1 in cervicovaginal secretions: comparison with nitrazine test and amniotic fluid volume assessment. Acta Obstet Gynecol Scand 2004; 83:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/30\">",
"      Gaucherand P, Salle B, Sergeant P, et al. Comparative study of three vaginal markers of the premature rupture of membranes. Insulin like growth factor binding protein 1 diamine-oxidase pH. Acta Obstet Gynecol Scand 1997; 76:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/31\">",
"      ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 2007; 109:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/32\">",
"      van der Ham DP, van der Heyden JL, Opmeer BC, et al. Management of late-preterm premature rupture of membranes: the PPROMEXIL-2 trial. Am J Obstet Gynecol 2012; 207:276.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/33\">",
"      Romero R, Hanaoka S, Mazor M, et al. Meconium-stained amniotic fluid: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol 1991; 164:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/34\">",
"      Duff P. Premature rupture of the membranes in term patients. Semin Perinatol 1996; 20:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/35\">",
"      Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol 1997; 177:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/36\">",
"      Clark P, Duff P. Inhibition of neutrophil oxidative burst and phagocytosis by meconium. Am J Obstet Gynecol 1995; 173:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/37\">",
"      Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; :CD004454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/38\">",
"      Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol 2001; 184:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/39\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 402: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2008; 111:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/40\">",
"      Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2010; :CD001058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/41\">",
"      Hutzal CE, Boyle EM, Kenyon SL, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol 2008; 199:620.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/42\">",
"      ACOG Committee Opinion No. 445: antibiotics for preterm labor. Obstet Gynecol 2009; 114:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/43\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/44\">",
"      Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997; 278:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/45\">",
"      Grigsby PL, Novy MJ, Sadowsky DW, et al. Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. Am J Obstet Gynecol 2012; 207:475.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/46\">",
"      Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 2008; 372:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/47\">",
"      Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/48\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/49\">",
"      Mackeen AD, Seibel-Seamon J, Grimes-Dennis J, et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev 2011; :CD007062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/50\">",
"      Carlan SJ, O'Brien WF, Parsons MT, Lense JJ. Preterm premature rupture of membranes: a randomized study of home versus hospital management. Obstet Gynecol 1993; 81:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/51\">",
"      Turnbull DA, Wilkinson C, Gerard K, et al. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004; 363:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/52\">",
"      Beckmann M, Gardener G. Hospital versus outpatient care for preterm pre-labour rupture of membranes. Aust N Z J Obstet Gynaecol 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/53\">",
"      Porat S, Amsalem H, Shah PS, Murphy KE. Transabdominal amnioinfusion for preterm premature rupture of membranes: a systematic review and metaanalysis of randomized and observational studies. Am J Obstet Gynecol 2012; 207:393.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/54\">",
"      Briery CM, Veillon EW, Klauser CK, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011; 204:54.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/55\">",
"      Hanley ML, Vintzileos AM. Biophysical testing in premature rupture of the membranes. Semin Perinatol 1996; 20:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/56\">",
"      Lewis DF, Adair CD, Weeks JW, et al. A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes. Am J Obstet Gynecol 1999; 181:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/57\">",
"      Leo MV, Skurnick JH, Ganesh VV, et al. Clinical chorioamnionitis is not predicted by umbilical artery Doppler velocimetry in patients with premature rupture of membranes. Obstet Gynecol 1992; 79:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/58\">",
"      Abramowicz JS, Sherer DM, Warsof SL, Levy DL. Fetoplacental and uteroplacental Doppler blood flow velocity analysis in premature rupture of membranes. Am J Perinatol 1992; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/59\">",
"      Carroll SG, Papaioannou S, Nicolaides KH. Doppler studies of the placental and fetal circulation in pregnancies with preterm prelabor amniorrhexis. Ultrasound Obstet Gynecol 1995; 5:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/60\">",
"      Melamed N, Ben-Haroush A, Pardo J, et al. Expectant management of preterm premature rupture of membranes: is it all about gestational age? Am J Obstet Gynecol 2011; 204:48.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/61\">",
"      Kunze M, Hart JE, Lynch AM, Gibbs RS. Intrapartum management of premature rupture of membranes: effect on cesarean delivery rate. Obstet Gynecol 2011; 118:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/62\">",
"      Lin MG, Nuthalapaty FS, Carver AR, et al. Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis. Obstet Gynecol 2005; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/63\">",
"      ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/31/15866/abstract/64\">",
"      Wolff K, Swahn ML, Westgren M. Balloon catheter for induction of labor in nulliparous women with prelabor rupture of the membranes at term. A preliminary report. Gynecol Obstet Invest 1998; 46:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6754 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15866=[""].join("\n");
var outline_f15_31_15866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Nitrazine and fern tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Instillation of indigo carmine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Placental alpha microglobulin-1 protein assay (AmniSure)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2872779931\">",
"      - Insulin-like growth factor binding protein 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H879788\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Meconium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antenatal corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24851190\">",
"      Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment of overt infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chemoprophylaxis for GBS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Women with HSV, HIV, or cerclage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tocolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Tissue sealants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6656918\">",
"      Amnioinfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Supplemental progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Maternal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Timing of delivery for expectantly managed pregnancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Method of delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Unfavorable cervix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159563783\">",
"      MANAGEMENT OF THE NEWBORN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6754|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?33/11/33982\" title=\"algorithm 1\">",
"      Algorithm for managing PPROM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?40/5/41054\" title=\"algorithm 2\">",
"      CDC algorithm for screening for GBS in preterm PROM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6754|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/53/848\" title=\"picture 1\">",
"      Nitrazine paper for pH testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/53/23386\" title=\"picture 2\">",
"      Ferning of amniotic fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/56/28553\" title=\"picture 3\">",
"      Ferning of cervical mucus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28428\" title=\"table 1\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/43/19131\" title=\"table 2\">",
"      Criteria for outpatient management of PPROM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/35/35387\" title=\"table 3\">",
"      Use of steroids and antibiotic in PPROM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43175?source=related_link\">",
"      Fetal membranes: Anatomy and biochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33001?source=related_link\">",
"      Genital herpes simplex virus infection and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4407?source=related_link\">",
"      Management of premature rupture of the fetal membranes at term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=related_link\">",
"      Midtrimester preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=related_link\">",
"      Patient information: Preterm premature rupture of membranes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37544?source=related_link\">",
"      Transvaginal cervical cerclage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_31_15867="Frequency ALL subtypes children";
var content_f15_31_15867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative frequency of acute lymphoblastic leukemia subtypes in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        ALL Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD Designation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-precursor ALL",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        10, 19, 20, 22, 24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-precursor with myeloid features",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Also express: 11, 13, 14, 15, 33, 34, 41, 42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mature B cell",
"       </td>",
"       <td>",
"        2 to 5",
"       </td>",
"       <td>",
"        10&plusmn;, 19, 20, 22, 25, sIg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T-cell",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        2,3,4,5,7,8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     slg: surface immunoglobulin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zipf, TF, Berg, SL, Roberts, WM, et al. Childhood Leukemias. In: Clinical Oncology (2nd ed), Abeloff, MD, Armitage, JO, Lichter, AS, et al (Eds), Churchill Livingstone, New York, 2000. p.2402. Copyright &copy; 2000 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15867=[""].join("\n");
var outline_f15_31_15867=null;
var title_f15_31_15868="Manifestations of gender based violence";
var content_f15_31_15868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Manifestations of gender-based violence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The family",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Physical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Murder, battering, genital mutilation, infanticide, deprivation of food, medical care, reproductive coercion/control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sexual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rape, incest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Emotional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confinement, forced marriage, threat of reprisals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The community (social reference)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Physical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Battery, physical chastisement, reproductive coercion/control, pernicious traditional practices",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Sexual assault",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rape, harassment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Workplace",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Sexual aggression: Harassment, intimidation",
"        </p>",
"        <p>",
"         Commercialized: Sex trafficking, prostitution",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Political",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        llegitimate detention, forced sterilization, forced pregnancies, tolerating gender violence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Custodial (military/police)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Child soldiers",
"        </p>",
"        Rape, torture",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: United Nations Population Fund Country Technical Services Team (CST). Violence against women: Issues and legislative responses in East and South-East Asia and the Pacific. UNFPA 2000. Updated information from the UNFPA is available at:",
"     <a href=\"file://asiapacific.unfpa.org/public/pid/6770\" style=\"font-style: italic;\" target=\"_blank\">",
"      file://asiapacific.unfpa.org/public/pid/6770",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15868=[""].join("\n");
var outline_f15_31_15868=null;
var title_f15_31_15869="Asthma control 12 and up";
var content_f15_31_15869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65972&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessing asthma control in youths greater than or equal to 12 years of age and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Components of control",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Classification of asthma control (youths &ge;12 years of age and adults)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Well-controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Not-well controlled",
"       </td>",
"       <td class=\"subtitle2\">",
"        Very poorly controlled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"9\">",
"        Impairment",
"       </td>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Throughout the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nighttime awakenings",
"       </td>",
"       <td>",
"        &le;2x/month",
"       </td>",
"       <td>",
"        1-3x/week",
"       </td>",
"       <td>",
"        &ge;4x/week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interference with normal activity",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Some limitation",
"       </td>",
"       <td>",
"        Extremely limited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-acting beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonist use for symptom control (not prevention of EIB)",
"       </td>",
"       <td>",
"        &le;2 days/week",
"       </td>",
"       <td>",
"        &gt;2 days/week",
"       </td>",
"       <td>",
"        Several times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        or peak flow",
"       </td>",
"       <td>",
"        &gt;80 percent predicted/personal best",
"       </td>",
"       <td>",
"        60-80 percent predicted/personal best",
"       </td>",
"       <td>",
"        &lt;60 percent predicted/personal best",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Validated questionnaires",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ATAQ",
"       </td>",
"       <td class=\"sublist_other\">",
"        0",
"       </td>",
"       <td class=\"sublist_other\">",
"        1-2",
"       </td>",
"       <td class=\"sublist_other\">",
"        3-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ACQ",
"       </td>",
"       <td class=\"sublist_other\">",
"        &le;0.75*",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;1.5",
"       </td>",
"       <td class=\"sublist_other\">",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        ACT",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;20",
"       </td>",
"       <td class=\"sublist_other\">",
"        16-19",
"       </td>",
"       <td class=\"sublist_other\">",
"        &le;15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Risk",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Exacerbations",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0-1/year",
"        </strong>",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         &ge;2/year (see footnote)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        <strong>",
"         Consider severity and interval since last exacerbation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive loss of lung function",
"       </td>",
"       <td colspan=\"3\">",
"        Evaluation requires long-term followup care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment-related adverse effects",
"       </td>",
"       <td colspan=\"3\">",
"        Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous 2-4 weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, there are inadequate data to correspond frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &ge;2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as patients who have not-well-controlled asthma, even in the absence of impairment levels consistent with not-well-controlled asthma.",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in 1 second; ATAQ: Asthma Therapy Assessment Questionnaire (Vollmer et al. 1999); ACQ: Asthma Control Questionnaire (Juniper et al. 1999b); ACT: Asthma Control Test (Nathan et al. 2004); N/A: not applicable.",
"     <br>",
"      * ACQ values of 0.76-1.4 are indeterminate regarding well-controlled asthma.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15869=[""].join("\n");
var outline_f15_31_15869=null;
var title_f15_31_15870="Middle phalanx fracture of proximal volar plate";
var content_f15_31_15870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Middle phalanx fracture of proximal volar plate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 198px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intraarticular fractures are commonly associated with soft tissue injuries, such as the volar plate injury depicted here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15870=[""].join("\n");
var outline_f15_31_15870=null;
var title_f15_31_15871="Aortic stenosis CW Doppler";
var content_f15_31_15871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Continuous wave Doppler shows a peak velocity across the aortic valve of 4.6 m/sec or a gradient of 85 mmHg compatible with severe aortic stenosis. No aortic regurgitation is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_31_15871=[""].join("\n");
var outline_f15_31_15871=null;
